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8.1 INTRODUCTION 
The presence of active pharmaceuticals ingredients (APIs) in aquatic systems has led in recent 
years to a burgeoning literature examining environmental occurrence, fate, effects, risk assessment, 
and treatability of these compounds. The vast preponderance of studies aimed at identifying and 
quantifying contaminant residues in aquatic tissues have involved the conventional and legacy pol-
lutants. Comparatively few studies have been targeted at APIs, primarily those that are lipophilic. 
Although APIs have received much attention as "emerging" contaminants of concern, it is impor-
tant to recognize that traditional approaches to understand and predict exposure and effects of other 
environmental organic contaminant classes mayor may not be appropriate for APIs. For exam-
ple, traditional approaches for understanding aquatic effects may not be as useful for some APIs 
(Brooks et al. 2003), but lessons learned from the study of compounds active at the hypothalamic-
pituitary-gonadal axis (endocrine disruptors/modulators) may reduce uncertainties associated with 
environmental assessments of other APIs (Ankley et al. 2007). 
Whereas APIs are often considered as a combined class of environmental contaminants, 
APIs include diverse groups of chemicals with physiochemical properties ranging in pharmaco-
logical potencies, environmental fate profiles, and patient usage patterns. Due to the relatively 
rudimentary state of knowledge for aquatic exposures to these substances, an understanding of 
critical body residues (CBRs) necessary to elicit pharmacologically and ecologically relevant 
responses is not available at this time. Because exposure does not necessarily evoke effects or 
risk, current challenges include understanding the relationship between exposure and effects 
within an ecological risk assessment framework. It appears particularly critical to understand 
whether internal pharmacological doses of APls in target tissues result from exposures at envi-
ronmentally relevant or realistic concentrations. Such information can inform ecological risk 
assessments examining the potential effects of APls based on their specific mechanism/mode 
of action (MOA). 
Tissue residues of contaminants are commonly used in retrospective ecological risk assessments 
to support an understanding of environmental exposure (Suter et al. 2000). Bioconcentration factors 
(BCFs) are useful in both retrospective and prospective assessments of traditional contaminants; 
BCFs are expressed as the ratios of concentrations in tissues (mass/kg) and the respective concen-
trations in the surrounding aqueous compartment (mass/L), resulting in units of Llkg. APIs are 
conceptually no different from these conventional contaminants because tissue residues can provide 
important information in exposure analysis, particularly when used as indicators of exposure in 
the field. Whole-body and tissue concentrations are essentially proxies for gauging the actual dose 
at the site(s) of action, which mayor may not be known. When bioconcentration occurs, an obvi-
ous advantage of measuring internal concentrations is when the external concentrations are below 
method detection limits (MDLs). 
Active Pharmaceutical Ingredients and Aquatic Organisms 289 
Compared with many conventional pollutants, APTs are in general comparatively more polar. 
They therefore tend to not partition to particulates and sediments, but rather remain dissolved in 
he aqueOUS phase. For those APIs that have significant tendency to become sediment-bound, little 
t ttention has been given to their bioavailability as measured by bioaccumulation. The measure of 
~ioaccumulation of a chemical associated with sediment is the biota-sediment accumulation factor 
(BSAF). The BSAF is expressed as a chemical's tissue concentration normalized to lipid content 
relative to its concentration normalized to sediment total organic carbon (Burkhard 2009). 
In this chapter we examine relevant information on residues in aquatic organisms, select factors 
influencing exposure, and available methods to understand relationships between exposure sce-
narios and effects thresholds. Though APIs are often combined with discussions of personal care 
products (PCPs) in the literature that has rapidly developed following publication of Daughton and 
Ternes (1999), we specifically focus on APIs for the purposes of this chapter. A broad literature on 
pCPs in aquatic organisms continues to develop (e.g., Mottaleb et al. 2009) and was recently sum-
marized by Ramirez (2007). 
An insight of particular importance concerns the level of knowledge regarding the linkage between 
exposure to APIs and adverse effects in aquatic organisms. Regardless of the available published 
data on exposure of aquatic organisms to APIs (and its size is indeed very limited, especially for 
real-world scenarios), it rarely intersects a complementary body of data for biological effects. When 
exposure data do exist, the same conditions, concentrations, and species have rarely been used in 
toxicity studies; parallel data sets are also usually disconnected temporally. Likewise, a considerable 
body of API data exists for effects, but exposure conditions (especially the API concentration or route 
of exposure) are often not environmentally realistic. The ability to routinely connect real-world API 
occurrence data to documented biological effects is therefore not yet available. Evidence for causality 
is probably strongest for sex steroids, largely because of their ubiquity and potencies; but even here, 
evidence can be confusing (e.g., see Vogeli 2008). A major challenge in establishing causality-a 
lack of correlation between tissue levels and observed effects-could well be the result of delayed 
effects, such as those only manifesting at later life stages but originating from exposure at earlier 
developmental stages; this is especially true for organisms with longer life cycles. 
8.2 EXPOSURE 
8.2.1 BACKGROUND 
The published literature on APIs as environmental contaminants is dominated with data on the 
analysis, occurrence, and fate of these chemicals in the environment, together with evaluation 
of waste and water treatment technologies. Surprisingly, comparatively little has been published 
regarding the aquatic toxicology of APIs, especially data relevant to exposure. Little information is 
available, for example, on the occurrence of APIs in aquatic organisms. This in itself is surprising 
given that predictive models for bioconcentration in fish are not yet up to the task, and empirical 
data are needed at least to validate computational approaches. The complexities and limitations of 
modeling bioconcentration of conventional pollutants (especially the legacy pollutants) in fish are 
discussed in detail by a number of authors (e.g., Geyer et a1. 2000, Gobas and Morrison 2000, Van 
der Oost et a1. 2003, Nichols et a1. 2007). 
The bulk of the studies on drug residues in aquatic tissues relate to what is known from aqua-
culture, where exposure is restricted to a very limited number of drugs (almost all being veterinary 
drugs) and at concentrations orders of magnitude higher than might occur in the ambient environ-
ment. Of the thousands of published studies that have been compiled regarding the many aspects 
of APIs as environmental pollutants (U.S. EPA 2009), roughly only 50 or so are directly relevant 
to aquatic exposure and tissue levels of APIs, and the majority of these studies have been published 
since Brooks et al. (2005) reported fish tissue residues of SSRIs (selective serotonin reuptake inhibi-
tors) from an effluent-dominated stream. 
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APIs have long been assumed to show little propensity to bioconcentrate, no less biomagnify, 
This has been based largely on their greater water solubility compared with conventional pollut-
ants such as pesticides and many industrial pollutants, especially the persistent organic pollutants 
(POPs). But APIs are known to sometimes undergo active transport, so this assumption may not be 
valid. Little is known for assisting the assessment of the bioaccumulation potential in fish (Cowan-
Ellsberry et al. 2008); even less is known regarding the bioconcentration of APIs by fish or other 
aquatic organisms. Bioaccumulation is deemed possible when the BCF (expressed as Llkg) exceeds 
a range of 500-5000, depending on the standard being applied (Cowan-Ellsberry et al. 2008). 
Even when definitive data have been obtained regarding bioconcentration, whether this can be 
extrapolated among species is unknown. Owen et al. (2007) emphasize the diversity in biology 
among the 28,000 species of fish. Tissue levels are governed largely by the pharmacokinetics of 
the API. These authors also point out that almost nothing is known regarding the pharmacokinetics 
of APIs in aquatic organisms-the xenoestrogen 17a-ethinyl estradiol (EE2) being one exception. 
Also, while it might be useful, extrapolations between mammals and fish can be challenging and 
potentially misleading because of key differences in physiology. Owen et al. (2007) stress that a pri-
mary route of uptake in fish is via the gills, from where blood is delivered to various organs before 
reaching the liver, in contrast to oral exposure in mammals, which leads to first-pass metabolism 
in the liver. Yet a further complication is the wide disparity that can exist among reported K"w data 
for a particular API; the ~,W is the octanol-water partition coefficient-the ratio of a chemical's 
equilibrium concentration in octanol versus water at a defined temperature. These values can range 
over several orders of magnitude, pointing to the need for empirical data with which to validate 
and develop better predictive models. As discussed later, site-specific pH can influence the ioni-
zation state of many APIs, reducing the utility of using Kow to predict exposure in retrospective 
evaluations; methodologies for estimating the BCFs for organic electrolytes have been assessed by 
Fu et al. (2009). 
Exposure is a term commonly used by toxicologists, modelers, and others involved with envi-
ronmental science. Exposure is a key component of the risk assessment paradigm that can provide 
insights for ways to reduce biological effects as well as better understand or predict their potential 
for occurring. Exposure translates the potential of hazard into the reality of risk (see Figure 8.1). 
But defining what is actually meant by exposure poses significant challenges. It does not necessar-
ily represent a discrete physical or temporal point in the complex series of events that determine 
the outcomes from physical contact of an organism with a chemical or other stressor. Rather, the 
processes involved with exposure are spread across a complex spatiotemporal continuum that links 
a stressor's source or origin with the eventual effects that might occur within biological systems. 
Although exposure includes understanding the duration, frequency, and magnitude to which 
organisms interact with biologically available contaminants, exposure magnitude is available for 
a limited number of APIs, and exposure duration and frequency is largely unknown for all APIs. 
Exposure is usually shown in conceptual diagrams as a standalone part of the hazard-risk contin-
uum, an example being shown in Figure 8.1. External factors may influence the bioavailability, 
absorption, and uptake of an API, while physiochemical properties of an API influences pharmaco-
logical bioavailability, and internal factors (e.g., metabolism) will influence the duration of internal 
dosimetry. Chemical exposure is often visualized as the physicochemical interaction of a biological 
receptor with the chemical stressor, as when a ligand binds with a receptor. In practice, however, 
separating exposure from effects can be arbitrary and at times confusing. This is especially true 
when discussing biomarkers of exposure and biomarkers of effects. 
A biomarker can be defined as pathway- or receptor-specific observations that are chemi-
cal-induced responses at the biochemical, physiological, or morphological level of an organism 
(Committee on Biological Markers of the National Research Council 1987). In ecotoxicology, bio-
markers represent critical measures to support an understanding of exposure and potential effects 
to environmental contaminants. Under prospective and retrospective ecological risk assessment 
frameworks, it is useful to classify the various sublethal responses organisms may exhibit following 
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FIGURE 8.1 Source-to-effects continuum generalized for chemical stressors (but all principles also apply to 
APls). The rounded rectangular boxes represent major points or processes in time or space along the source-
to-effects continuum. The ovalized rectangular boxes and arrow labels represent variables that affect the 
processes along the continuum. The SCALE arrow represents the level of biological organization that the 
stressor impacts. 
exposure to contaminants as either biomarkers of exposure or biomarkers of effect (Huggett et al. 
1992). Biomarkers of exposure differ from biomarkers of effect in that these measures inform 
whether an organism has been exposed to contaminants (e.g., gene expression) but do not necessarily 
allow for determination of whether the organism has been adversely impaired. Biomarkers of effect 
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(e.g., egg shell thinning, histopathology), however, are indicators of ecotoxicity, especially when 
measures of an adverse effect can be linked to a physiologically and ecologically relevant endpoint 
(e.g., growth) with population-level relevance (Ankley et al. 2007, Brain et al. 2008a). Biomarkers 
of exposure and effect have been successfully employed in a variety of retrospective ecological risk 
assessments (Suter et al. 2000), and their use in prospective environmental risk assessment is pro-
jected to increase due to a number of factors. Environmental contaminants such as APIs that may 
exert toxicity through receptor/enzyme interactions are providing an impetus toward "intelligent" 
ecotoxicity testing, which requires development and interpretation of biomarkers. 
Regardless of the difficulty in providing a rigorous definition of exposure, the general concept 
of exposure is essential for organizing discussions about assessing risk. In this chapter, we use expo-
sure as the framework to better understand the ramifications of APIs in the aquatic environment. 
After all, in the absence of exposure, hazard cannot translate into risk. Likewise, exposure does 
not necessarily pose ecologically relevant risk levels-for example, if perturbation of homeostasis 
does not result. 
The prime aspect of exposure that creates the potential for a cascade of events within biological 
systems is the initial physical association or interaction of chemical stressors with an organism. In 
the aquatic environment, a prime sign of exposure is the simple occurrence of a stressor within one 
or more tissues, such as blood, lipid, muscle, bile, liver, ovaries, eggs, or brain. The factors driving 
the partitioning and distribution of APIs within fish are incompletely understood. For example, 
fish have a variety of chromatophores, some of which are pigment-containing, such as melano-
cytes (New World Encyclopedia contributors August 13, 2008). During development, pigmented 
melanocytes begin appearing within a day of fertilization. The potential significance of these cells 
to exposure is related to their high binding affinities for a broad spectrum of xenobiotics, including 
a wide array of APls known for high affinity to melanin (Testorf et al. 2001, Aubry 2002, Roffey 
et al. 2007). Since humans only have melanocyte chromatophores, melanin has been most studied. 
Binding to melanin is known to lead to drug accumulation, one of the routes resulting in the concen-
tration of drugs in hair (Larsson 1993). In fish, binding to melanin (and possibly to other pigments) 
could lead to API reservoirs within certain tissues. 
APIs introduced to the aquatic environment via sewage pose additional challenges in assessing 
exposure. Because of extreme spatiotemporal fluctuations in concentrations, how accurately can 
exposure be assessed on the basis of monitoring residues in water? This is especially true for APIs 
that are released episodically, whether event-driven (such as by the sporadic practice of disposal) or 
when discharged by diurnal patterns in flushing of sewers or when influenced by seasonality (which 
can affect waste treatment efficiency as well as the types and quantities of individual APIs that are 
being used). These factors can result in high but transient concentrations, strongly influencing expo-
sure magnitude, duration, and frequency (Daughton 2007). Traditional sampling using discrete grab 
samples may not be representative of longer term exposure levels. Passive, integrative samplers can 
overcome some of these limitations (e.g., Vermeirssen et al. 2008), though the applicability has not 
been demonstrated for a broad range of APls, and samplers do not characterize all routes of expo-
sure (e.g., dietary). 
A body of published work points to a spectrum of potential toxicological consequences follow-
ing controlled exposure of certain aquatic organisms to a limited number of APls, but these studies 
ignore whether real-world exposures actually occur and whether they occur at the requisite real-
istic concentrations (e.g., Gaworecki and Klaine 2008). Often, effects using traditional endpoints 
(e.g., survival, growth, and reproduction) in traditional test species (e.g., Ceriodaphnia dubia) are 
found only at levels orders of magnitude higher than known in the environment (e.g., Henry and 
Black 2008). Such observations are generally supported by several recent papers that reviewed 
information on aquatic toxicity of APIs (Crane et al. 2006, Fent et al. 2006, Farre et al. 2008). 
Rather than repeating such efforts here, it is instead important to keep in mind that the effects 
level is a function of the sensitivity of the targeted endpoint in the test species selected for study; 
other endpoints-especially those still not recognized-may have lower effective concentrations 
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(below current NOAELs-no observable adverse effect levels), particularly from standardized 
ecotoxicity assays. 
Determining whether a more sensitive endpoint represents an ecologically relevant measure of 
effect amenable to inclusion in effects analysis of an ecological risk assessment must be considered 
for APIs (Ankley et al. 2007). For example, the ecologically relevant fathead minnow reproduction 
and feeding behavior endpoints are more sensitive to EE2 (Ankley et al. 2001) and ftuoxetine (Stanley 
et al. 2007), respectively, than 7-day juvenile fathead minnow growth, which is routinely employed 
prospectively to assess sublethal effects of individual chemicals, ambient toxicity in surface waters, 
and whole-effluent toxicity. Other endpoints, which may represent ecologically relevant biomarkers 
of effect, should be mechanistically linked to ecologically relevant endpoints (Ankley et al. 2007) 
that can be integrated in ecological risk assessments (Brooks et al. 2009b). One recent example 
of an ecologically relevant and more sensitive endpoint than traditional morphometric responses 
(e.g., growth) was presented by Brain et al. (200Sb). Disruption of the folate biosynthetic pathway 
in aquatic plants was demonstrated following sublethal exposure to sulfamethoxazole at concentra-
tions more than an order of magnitude lower than for growth impairment (Brain et al. 200Sb). 
Why should we care about exposure? Better understanding of exposure provides the opportunity 
to look both backward and forward in the hazard-risk continuum-ranging from sources to effects. 
Measurement of exposure can be used in a retrospective ecological risk assessment, for example, 
to reveal sources of contamination, measure site-remediation success, as a surrogate measure of 
contaminant concentrations, or to reconstruct dose, or in a prospective ecological risk assessment to 
estimate the possibility of disease and its time of onset. Some of the major reasons for understand-
ing and measuring exposure in the aquatic environment are captured in Table S.l. 
TABLE 8.1 
The Importance of Understanding or Measuring Aquatic Exposure 
Aquatic Exposure Data Can Be 
Used For 
Advanced warning of effects 
Prognosis or vulnerability 
Reveal potential for subtle effects 
Prioritization of APIs 
Reveal i nadeq uacieslflaws in 
models 
Reveal potential for food chain 
disturbances 
Sentinel for terrestrial organism 
exposure 
Potential for human exposure 
Corroborate representativeness or 
need for toxicity testing 
Rationale 
Measure potential for adverse population-level effects or individual effects (in the 
case of threatened and endangered species), should the level of exposure be 
sustained or rise, or should the onset of effects be delayed. 
Predict the likelihood of, or vulnerability for, future disease onset should exposure 
occur. 
Provide insights on the potential for cumulative subtle etfects that might go 
unnoticed until a level of irreversible harm has been reached. 
Exposure studies can inform, direct, and guide the selection of APIs for more 
in-depth toxicological study; likewise, occurrence studies (such as from water 
monitoring), can be used to guide exposure studies. 
Bioconcentrated/bioaccumulated body burdens often do not comport with 
predictive models (e.g., Maunder et al. 2007). 
When bioconcentration and bioaccumulation resist predictive modeling, analysis of 
tissue levels are therefore required. 
Being more susceptible to exposure than terrestrial organisms and for development 
of subtle effects, aquatic exposure can serve as a sentinel model for terrestrial 
exposures (such as might occur from the recycling of treated sewage). 
Can provide information on levels of potential stressors that humans might 
consume via the food chain (e.g., contaminated fish in the diet). 
Establish whether concentrations/doses used in toxicity testing actually occur in 
the wild. 
continued 
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TABLE 8.1 (continued) 
The Importance of Understanding or Measuring Aquatic Exposure 
Aquatic Exposure Data Can Be 
Used For 
Stressor sources/origins/ 
distributions 
Pollution prevention/source control 
Gauge success/progress of cleanup 
or remediation efforts, or of new 
waste treatment technologies 
Surrogate measure of pollutant 
concentrations 
Inadequacy in water monitoring for 
predicting exposure 
Magnify levels of stressors not 
ordinarily toxic 
Magnify levels of stressors not 
ordinarily detectable 
Exposure times extended in 
absence of stressor in ambient 
environment 
Dose reconstruction 
Correlate ambient, external 
concentrations with exposure 
Deconvolute contributions to 
biological effects originating from 
natural (ambient) background 
Detecting newly emerging stressors 
Rationale 
Tissue concentrations can help to reveal the locations, distributions, frequencies, or 
durations of stressor presence in the ambient environment. 
Guide actions to prevent or control the source or origin of the stressors, thereby 
reducing the potential for exposure. 
Tissue levels of chemical stressors used to measure ambient concentrations after 
cleanup actions or remediation, or after implementing new control measures at 
sewage treatment facilities. 
Tissue levels of chemical stressors used as surrogate measures of ambient 
concentrations of APls in water. 
Extreme spatiotemporal fluctuations in water concentrations of APIs obscure or 
complicate evaluation of actual exposure. This is especially true for APIs that are: 
(i) released episodically (event-driven. such as by the sporadic practice of disposal 
or events causing large changes in usage rates or in the types of medication being 
used), (ii) discharged by diurnal patterns in flushing, (iii) influenced by 
seasonality. Tissue levels may serve to integrate exposure over time. 
Uptake and bioconcentration of chemical stressors at concentrations below 
no-effect levels in water can eventually achieve body-burden levels that exceed 
effects levels. 
When stressors can be bioconcentrated, exposed organisms serve as sentinels for 
sources of pollution or ambient levels that might otherwise be too small to 
directly detect. 
Biomagnified residues extend the time during which exposure can occur, even after 
the API is no longer present in the external environment. 
Levels of exposure can be used to reconstruct the original dose. 
If actual exposure can be calibrated to external exposure levels, then simple 
chemical monitoring in water could possibly be used instead of more resource-
intensive tissue monitoring for predicting exposure. 
Natural incidence can playa role in certain biological conditions that also result 
from exposure to stressors. Natural background can be confused with effect. 
Understanding exposure helps to distinguish the two causes (e.g., Grim et al. 
2007). 
Identifying previously unknown chemicals concentrated in tissues can reveal newly 
emerging pollutants before any linkage with effects might be suspected; this is 
particularly germane to new drug entities recently introduced to commerce. 
Remarkably, given the voluminous literature on APls in the aquatic environment, little data exist 
relevant to the occurrence of APIs as residues in the tissues of aquatic organisms. These limited data 
come primarily from controlled studies using APls postulated or known to occur in the environ-
ment. These studies involve exposure experiments under controlled conditions (including fish caged 
in the wild) and especially from studies of veterinary drug residues in aquacultured fish. Another 
source of data exists in the form of calculated BCFs from predictive models. One of the ramifica-
tions of this is that except for the expected residues of certain veterinary APIs used in aquaculture, 
it is essentially unknown what levels of the numerous APIs occurring in the ambient environment 
might lead to human exposure via consumption of fish or other aquatic life. No human exposure 
studies have been done on API residues in wild fish. It is known, however, that tissue residues of 
certain APIs in aquacultured fish can resist degradation during cooking and can migrate from one 
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tissue to another during cooking, as shown for the antibiotics oxolinic acid (OA) and flumequine 
(Steffenak et al. 1994). 
8.2.2 SOURCES/ORIGINS LEADING TO EXPOSURE 
Thousands of distinct chemicals are formulated into tens of thousands of commercial products used 
worldwide in the practice of human and veterinary medicine or for personal care. Those of most 
interest in the aquatic environment include the APls that: (i) are most frequently used or used in the 
greatest quantities (e.g., NSAIDs: nonsteroidal anti-inflammatory drugs) or which are commonly dis-
posed by flushing into sewers, (ii) are the most potent (e.g., synthetic hormones such as EE2) or that 
have clear potential for environmental effects (such as antibiotics, serotonin regulators, or oncolytics), 
(iii) are excreted largely unchanged, (iv) share like-modes or mechanisms of action and which could 
therefore act by concentration addition (e.g., SSRI antidepressants), and (v) can bioconcentrate. 
The occurrence and disposition of APls in the environment is best viewed in terms of their 
origins or sources, which comprise the locations from which they enter the environment and the 
pathways by which they enter (and are initially distributed within) the environment. These are many 
and varied, and even a simplified network flowchart can seem complex (see Figure 1 in Daughton 
2008). The major sources that have the potential for impacting the aquatic environment are sum-
marized in Table 8.2; an overview of the many sources and origins of APls in the environment is 
TABLE 8.2 
Sources/Origins of APls Significant to Aquatic Exposure 
API Source/Origin 
Human and veterinary 
medications 
Dual-use 
Chemical categories 
Description/Explanation of API Source 
Human medications (over-the-counter; prescription only or legend drugs) include thousands 
of distinct APIs comprising numerous categories used in diagnostics, prophylaxis (including 
vaccines), cosmetics, lifestyle, and therapy. Veterinary medications (including those used in 
aquaculture) primarily comprise anabolic steroids, parasiticides, and antibiotics, though other 
medicines are also used for companion animals (e.g., fluoxetine). 
Some APIs also have uses outside the practice of medicine. Some have dual use as pesticides 
(e.g., lindane, pyrethrins, avermectins, azole fungicides, and warfarin); another example is 
malachite green, a chemical used illegally in aquaculture but where aquatic exposure has 
been documented as a result of other uses (Schuetze et a!. 2008). Some veterinary medicines 
have even been evaluated for nonaquaculture pesticidal use directly in the aquatic 
environment; for example, the sedative medetomidine has been proven effective as an 
antifouling agent against barnacles (Hilvarsson et a!. 2007). 
Lower and higher Mw synthetics; biologics (derived from organisms; e.g., antibodies, 
vaccines, and interleukins); natural products; nanomedicines; halogenated APTs are common 
(especially those containing fluorine). 
DBPs and transformation Little is known regarding the halogenated disinfection by-products (DBPs) that might be 
pmducts created from any number of APTs (e.g., Flores and Hill 2008); many metabolites or 
environmental transformation products can be bioactive. 
Manufacturing Release in effluent from pretreated and untreated APT manufacturing; perhaps a minor, 
Excretion 
localized source in the United States, but possibly of greater significance in less developed 
countries (e.g., Larsson et a!. 2007; Fick et a!. 20(9). 
Pharmacokinetics for humans differ radically among APls, resulting in wide spans in 
excretion efficiency of unmetabolized parent APls or in excretion of biologically active 
metabolites; conjugates can act as reservoirs of parent APls once hydrolyzed during sewage 
treatment or in the environment. Excretion apportioned between the feces and urine varies 
among APls. Maternal-fetal transport of APTs in fish is not understood. 
continued 
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TABLE 8.2 (continued) 
Sources/Origins of APls Significant to Aquatic Exposure 
API Source/Origin 
Bathing 
Sewerage 
Treated sewage effluent 
Biosolids, manure, pet 
excrement 
Runoff 
Wet-weather overflows 
and straightpiping 
Locations where unused 
medications accumulate 
Disposal to sewerage 
Disposal to domestic 
trash 
Commercial use 
Vaporization! 
aerosolization 
Description/Explanation of API Source 
Bathing and swimming release APIs directly to sewers or surface waters by two mechanisms, 
both involving dissolution of APIs: (i) from medications applied directly to the skin, and 
(ii) after excretion to the skin via sweat (Daughton and Ruhoy 2009), 
Only the contributions from distributed sewer systems can directly impact the aquatic 
environment; septic and advanced on site systems generally do not serve as direct sources, but 
can be important in extreme conditions (e.g., improperly installed leach fields, direct 
discharge from advanced onsite systems). Straightpiping of untreated sewage continues to be 
practiced in some locales. Wet-weather events can cause discharge of untreated sewage. 
The removal efficiency of APls from the influents to WWTPs varies greatly-from 0 to 
essentially 100%, as a function of the properties of the individual API and the type of 
treatment being used. Removal includes "destruction" (alteration of chemical structure) as 
well as physical sequestration, such as by filtration or sorption to sludge (and subsequent 
creation of "biosolids"). 
One disposal option for biosolids (treated sewage sludges), which can contain sorbed or 
occluded APls, is amendment of agricultural soils; wet-weather runoff holds the potential for 
transporting these APls to surface water via runoff; manure from farm animals and 
excrement from medicated pets can also serve as a source (via wet-weather runoff). 
Primarily relevant to veterinary drugs from CAFOs (e.g., wet-weather flooding of retention 
ponds) or leaching of manure or feces from domestic animals and pets; can also involve 
human medications, which are experiencing growing usage with pets. 
Flows that exceed the capacity of sewage treatment plants and rural areas where sewers still 
discharge directly to surface waters represent worst-case sources (e.g., combined sewer 
overflows), as the concentrations of APIs in these waste streams would not be reduced by 
treatment. 
Leftover drugs tend to accumulate (and eventually require disposal from) a wide expanse of 
locations, extending far beyond the domestic medicine cabinet (Ruhoy and Daughton 2008). 
Unwanted medications are often disposed by flushing down sewer drains; this can involve 
leftover, unused medications and also the residuals contained in used containers or delivery 
devices (Ruhoy and Daughton 2(08). 
Instead of disposal to sewerage, leftover medications are also disposed to domestic trash (this 
is currently the preferred method recommended by the U.S. federal government, when 
alternative collection options are not available) (U.S. FDA 2010; ONDCP 2009 [updated 
October]). The leachate collected from trash disposed in engineered landfills is sometimes 
returned to sewage treatment facilities, possibly serving only as a minor and indirect route to 
the aquatic environment. 
Agriculture (antibiotics) and aquaculture (medicated feeds) serve as sources in localized 
environments; these sources can involve significant quantities of APIs, especially uneaten 
medicated feeds (Rigos et al. 2(04). 
The vapor pressure (volatility) for the vast preponderance of APls is insufficient to serve as a 
source (or route of loss) for the aquatic environment: vaporization might, however, serve as a 
source for certain PCPs, such as synthetic musks (Aschmann et al. 200 I; Peck and 
Hornbuckle 2004, 2006) and cyclic methylsiloxanes (Xu and Chandra 1999); indeed, 
Galaxolide has been detected in the blubber from Antarctic fur seal (Arctocephalus gazelia) 
from the South Shetland Islands (Corsolini 2009). APls can also get entrained on particulates 
that can then become airborne (Ham scher et al. 2003; Cecinato and Balducci 2(07). 
Note: An overview of sources and origins of APls in the environment is also provided by Daughton (2007, 2008). 
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provided by Daughton (2007, 2008). Sources and origins are important to understand not just for 
exposure. A comprehensive inventory of sources and their individual significance relative to each 
other with respect to contributions to environmental loadings can facilitate the prioritization of 
actions needed to reduce, minimize, or eliminate the potential for exposure via source reduction or 
pollution prevention. A complex array of processes acts upon APIs released into sewage to diminish 
their ultimate concentrations in the aquatic environment. One example situation using the fluoroqui-
nolones is provided by Golet et al. (2002). 
8.2.3 EXPOSURE VARIABLES 
A vast and complex array of variables and their interactions (involving both the stressor and the 
target organism) dictate how and to what degree exposure occurs. These include the routes and 
processes by which exposure occurs. Few of these variables are unique to aquatic exposure involv-
ing APTs, and all can play roles, either in concert or in sequence. Not all of the variables, however, 
have been examined with respect to APIs. Many are relevant to controlled exposure studies and 
therefore only have hypothetical applicability to exposure in the wild. Table 8.3 summarizes some 
of the many aspects relevant to aquatic exposure and provides examples from the literature. Some 
of these factors are incorporated in the conceptualized diagram of the "4Ts": toxicant, totality, tol-
erance, and trajectory (Daughton 2005). It is also important to recognize that just because a chem-
ical stressor might not be detectable in any tissue does not mean that exposure has not occurred. 
It could be that the analytical methodology cannot detect the stressor at a sufficiently low level 
(the MDL is too high). After all, some concentration levels known to have effects are extraordi-
narily low. For example, effects from EE2 have been documented at the sub-ppt level in surround-
ing water (i.e., 0.05 ng/L) (Larsen et a1. 2008); diclofenac is purported to have pro-inflammatory 
effects at concentrations as low as 10-14 M (-3 pg/L) (Schirmer and Schirmer 2008). Moreover, the 
kinetics involved with the processes governing exposure might be sufficiently fast that uptake by 
an organism results in immediate formation of irreversible products of exposure, such as adducts, 
or in metabolic transformation to bioactive products. These products might merely be biomarkers 
of exposure or they might alternatively be biomarkers of effect. Regardless, in these situations 
monitoring for tissue residues of the parent API may well yield negative data, and therefore expo-
sure can be overlooked or underestimated. 
The internal dose is a function of the external concentration, chemical state of the API (e.g., 
ionization), uptake by and distribution within the organism, and bioavailability. Since the amount of 
stressor that actually interacts with receptors of toxicological consequence cannot be easily deter-
mined, surrogate measures are usually used to estimate the actual biologically effective dose. An 
added difficulty arises in translating "concentrations" associated with sediments and particulates 
to freely available portions. Studies of uptake from sediments are not common, one example being 
Higgins et a1. (2009), who report on the uptake by an oligochaete of triclocarban. 
8.2.4 SOME GENERAL PERSPECTIVES AND BACKGROUND 
REGARDING AQUATIC TISSUE LEVELS OF APls 
Surprisingly few studies have been published that examine the occurrence of APIs not just in fish 
but in any aquatic animal or plant. Moreover, most of these data have been obtained for veterinary 
APIs (primarily antibiotics and estrogenic/androgenic steroids), which are used in aquaculture at 
levels hir exceeding those found in the ambient environment. Most aquatic biomonitoring studies 
designed to emulate exposure under ambient environmental conditions are performed under con-
trolled conditions, often with exposure concentrations still exceeding those that would be found in 
the ambient environment. Controlled exposure studies often use exposure concentrations that are 
one or more orders of magnitude higher than those that exist in the ambient environment, usually to 
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TABLE 8.3 
Variables Involved with Aquatic Exposure 
Variable Affecting 
Exposure 
Exposure under 
controlled 
conditions 
Route of exposure 
(free in wild) 
Type of organism 
Environmental 
location 
Stressor physical 
status 
Stressor properties 
Ambient 
environment 
Example 
Baths (immersion in static, replacement, or flow-through systems, sometimes using whole effluent 
from sewage treatment or water collected from native environments), oral (bolus), injection (IP), 
feeding, caged in wild, whole-effluent toxicity testing. 
Gill (brachial) transport, dermal absorption, oral/gut, olfactory (e.g., transport of nanoparticles via 
olfactory neurons), lateral-line sensory organ (e.g., Chiu et al. 2008). 
Teleost and cartilaginous fish, macroinvertebrates (invertebrates such as insects, crustaceans, 
mollusks, and worms), periphyton (e.g., Aufwuchs), plants, amphibians, and reptiles, waterfowl, 
and mammals (e.g., otters). 
River, wetland, lake, reservoir, estuary, marine; benthic, pelagic, interfacial monomolecular 
monolayer; proximity to effluent from treated effluent discharge or raw sewage. 
Dissolved in water column, particulate-bound (including incorporation into feed), sediment-bound; 
uptake from water can differ dramatically from dietary uptake. 
Water solubility, Kow' pKa, log D, log K"pw, MW, molecular size or cross section, molecular 
conformation and steric factors, environmental/metabolic half-life, chirality, vapor pressure. 
pH, temperature (or season), salinity, total dissolved solids, natural organic matter (Galvez et al. 
2(08), dissolved oxygen or hypoxia, solar irradiance (photolysis), nutrient levels and turbidity 
(Gordon et al. 2(06), geographic locale, and dilution (e.g., effluent-dominated streams yield 
maximum concentrations). Season can affect performance of sewage treatment (e.g., via 
temperature) and irradiance (e.g., for photolysis or growth of autotrophs). Season and locale can 
also affect the types of APIs present in sewage because different medications are used in different 
seasons and in ditIerent locales. 
Engineering controls End-of~pipe treatment can reduce concentrations of some but not all APls; it can also lead to the 
formation of biologically active products and API-based DBPs; efficiency is a function of the types of 
engineered treatments used by manufacturers and municipalities (e.g., Snyder et al. 2007). Types and 
Fate 
Organism status 
Organism behavior 
and niche 
Timing of exposure 
Magnitude of 
exposure 
efficiencies of treatment can vary considerably from country to country (e.g., see Larsson et al. 2(07), 
The interactions of the stressor with the ambient environment dictate its fate; key processes are 
microbial degradation, photolysis, and sequestration via sorption to sediments. But even short 
environmental half-lives do not preclude a continual presence of those stressors that are continually 
introduced, such as via treated sewage; this has been termed "pseudopersistence" (Daughton 2002). 
Food supply, nutrient levels, health, prior exposure history, growth state, lipid content, injuries, 
disease, age, gender, condition index/factor, body length, over-expressionlinhibition of efflux 
pumps, species/strain. For example, nutrient concentrations and stoichiometry influence lower 
trophic-level responses to triclosan (Fulton et al. 20(9). 
Behavior involving feeding (free-feeding, sessile, filter-feeding), niche, trophic level, swimming/ 
migratory behavior, and attraction/avoidance, and how these influence proximity to source 
(e.g., sewage outfalls) and aggregation; aquatic, marine, estuarine. 
Windows of vulnerability, developmental life stage/reproductive status (e.g., embryo, egg, larval, 
hatchling, fry, juvenile, adult, spawning) (Van Aerie et al. 2002). Simultaneous vs. sequential 
exposure when multiple stressors are involved. 
Aqueous concentration is a major determinant of actual internal exposure dose for aquatic 
organisms. For APls, concentration is partly dictated by the degree of dilution in waters receiving 
treated or raw sewage effluent (with effluent-dominated streams and streams receiving raw sewage 
representing worst cases); other determinants include popUlation served, sewage flow rate, and 
treatment technology. High stressor concentrations in controlled laboratory studies are often not 
relevant to real-world exposure. Newer exposure studies, however, are exploring lower and lower 
concentrations; need to ensure that studies are relevant to the real world (Hinton et al. 20(5). 
BCFs are often higher at lower concentrations. Lack of exposure or etl'ects at higher 
concentrations cannot be used to rule out the importance of lower concentrations because of 
multiphasic and nonmonotonic dose-response. 
Active Pharmaceutical Ingredients and Aquatic Organisms 299 
TABLE 8.3 (continued) 
Variables Involved with Aquatic Exposure 
Variable Affecting 
Exposure Example 
Duration/variability/ Constant, pulsed, discrete, episodic, acute/chronic, life cycle, and multi generational. 
frequency of 
exposure 
Multiple stressors 
Exposure history 
Pharmacokinetics 
Pharmacological 
bioavailability 
Aquatic 
bioavailability 
Transformation 
products 
Resiliency/ 
vulnerability 
Biological 
modulators of 
exposure 
Simultaneous versus sequential exposure to multiple stressors. Multistressor interaction etfects 
(e.g., additive, potentiated, antagonistic, and synergistic) may follow concentration addition or 
independent action models; competition for-or facilitation of-transport across membranes. 
Prior or simultaneous exposure to other stressors-both chemical and physical (e.g., temperature, 
salinity, stress from prey, etc.). 
ADME: absorption, distribution, metabolism (e.g., phase I and II), excretion/elimination-all 
affecting half-life and disposition within organism (including depuration); reactivity within 
organism (e.g., formation of adducts vs. bioconcentration within lipid). 
Residues that are bound versus those that are free (e.g., particulate-bound APIs may not transport 
across gills); sequestration and/or bioconcentration of body residues, e.g., within lipids, binding 
with melanins (Larsson 1993; Testorf et al. 2001; Aubry 2002; Roffey et al. 2007) and as other 
adducts; disposition in blood/plasma (primarily bound to proteins), muscle, bile, liver, brain, 
gonads, eggs, skin, bone, etc.; these factors also have direct relevance to subsequent human 
exposure to APls via the food chain (function of edible tissue distribution). 
pH influence on ionization state and lipophilicity of APIs. Influence of sorption to suspended 
particulate matter. Concentration enrichment within sediments. For example, higher Ko values 
were observed for ciprofloxacin with fine particulate organic matter (FPOM) than coarse 
particulate organic matter, resulting in a higher magnitude of exposure to benthic 
macroinvertebrates consuming FPOM (e.g., collector-gatherers) (Belden et al. 2007). 
Metabolites and environmental transformation products (e.g., degradates from photolysis or 
halogenation during disinfection) may prove more important that the parent API. 
Biochemical, physiological, and behavioral repertoire of an organism that determines its ability to 
avoid exposure or reduce its magnitude or duration; ability to maintain internal homeostasis and 
adapt to stressors (Clubbs and Brooks 2007). 
Various biological processes can enhance, facilitate, or reduce exposure. Those that are 
evolutionarily conserved play key roles. Among the most important considerations include 
variations of API metabolism among aquatic organisms. Exposure defenses include p-GP efflux 
pumps, which can also be induced/repressed by other stressors, especially APIs (see: Tan 2007); 
cellular stress response (e.g., induction of heat shock proteins); facilitation might occur via active 
transport (e.g., for APIs of low 1\,," or high MW). 
NOIe: Some of these factors are discussed in detail by Geyer et al. (2000) and van der Oost (2003). 
maximize the chances of detecting and quantifying any amount that might accumulate. Most of the 
aquatic studies involving human APIs have been published only in the last few years. 
Some studies examine the presence of APIs (primarily estrogens) indirectly, by way of activity 
assays. For example, Houtman et al. (2004) examined fish bile for estrogenic activity; but fraction-
ation of the sample is required for assigning activity to a particular API. It is also important to note 
that in many studies, especially those examining bile, the APIs can be present as metabolically 
reversible conjugates, which mayor may not have been cleaved prior to analysis; so the API is not 
really present in its parent form, although it can be reabsorbed once the conjugate is excreted into 
the intestine, The interpretation of tissue levels of many APIs, especially the steroids, is greatly 
complicated by the relative portions that are free versus conjugated. 
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The analysis of bile for free and especially conjugated APIs has been well-established for over 30 
years. In a summary of data acquired in the 1970s for over a dozen APIs, concentration in the bile 
of the dogfish shark was already known (Guarino and Lech 1986). Concentrations in the bile versus 
plasma were known to range up to factors of hundreds (e.g., warfarin and diethylstilbestrol) or thou-
sands (e.g., methotrexate). The utility of bile in exposure monitoring is discussed by Adolfsson-Erici 
(2005) and Pettersson (2006). 
Almost no tissue-monitoring study has examined the optical isomer ratios of racemic APIs; 
indeed, even the aquatic toxicity of chiral APIs has been little studied, with Stanley et al. (2006) pub-
lishing one of the first studies (with propranolol). Stanley et al. (2007) further examined enantiomer-
specific sublethal effects of the antidepressant f1uoxetine on traditional endpoints (survival and 
growth) and the ecologically relevant behavioral response of feeding behavior. Both studies by 
Stanley et al. (2006, 2007) indicated that the more pharmacologically active enantiomer was more 
toxic to fish when sublethal rather than lethal responses were examined. Clearly enantiomer-specific 
bioaccumulation and effects of chiral compounds require additional attention and may necessitate a 
priori considerations in ecological risk assessments (Stanley and Brooks 2009). 
Although the significance of bioconcentration is largely one of establishing potential internal 
dose, it is important to note that internal exposure is not necessary for an effect to occur. Certain 
effects can occur when the target organ is external. This is the case, for example, with exposure of the 
lateral-line sensory organ (e.g., Chiu et al. 2008) and for olfactory and taste exposure. Theoretically, 
antibiotics could alter the natural community structure of microorganisms that reside on the exter-
nal surfaces of any aquatic organism. 
An important perspective regarding the range of APls and metabolites that have been and will 
continue to be detected in aquatic tissues is that of "self-biasing detectability." Those APls with the 
highest probability of being detected are those that (i) can be taken up from water or food, (ii) are 
present in the highest concentrations, (iii) have the lowest MDLs, and (iv) have available appropriate 
analytical reference standards. Regarding the second point, those present in the highest concentra-
tions tend to be those with the higher required doses, and which therefore have lower potency (the 
human acceptable daily intakes [ADIs] for residues of veterinary APIs in food therefore tend to also 
be higher). The third point is rarely pointed out. MDLs among APIs in a particular tissue can vary 
by more than 2 orders of magnitude. This means that APIs commonly present in tissues but having 
high MDLs might not be detected. As an example, Ramirez (2007) targeted 25 APIs/metabolites 
in fish in effluent-dominated streams and rivers. Of the seven that were detected, three had the low-
est MDLs. Of the seven APTs with the highest MDLs, only one (gemfibrozil) was detected. Tissue 
concentrations below 0.1-1 f,lg/kg are rarely reported because this usually falls below the current 
method detection capability, primarily because of matrix interferences. But APIs could nonethe-
less be present at these levels and will therefore be overlooked or self-censored. In the case of API 
metabolites, very few deuterated standard compounds are commercially available, which presum-
ably has precluded their analyses in tissues compared with parent drugs. 
8.2.5 PREDICTIVE MODELING 
Empirical data for the uptake and bioconcentration of APTs by aquatic organisms is very limited. Such 
data are primarily focused on the legacy POPs. The empirical data that do exist are fraught with quality 
issues and uncertainty; extrapolations across chemical classes or aquatic species are notoriously unreli-
able. Acquiring empirical data is met with a number of hurdles, not the least of which are cost and ani-
mal welfare concerns. Data from real-world field conditions are even more limited than data obtained 
under controlled laboratory conditions, and these data are poorly covered in the available electronic 
databases. The bioaccumulation databases for fish have been summarized by Weisbrod et ai. (2007); 
in vitro methods for measuring bioavailability in fish have been reviewed by Weisbrod et ai. (2009). 
A comprehensive review of the literature on uptake and bioconcentration of organic chemicals by 
aquatic organisms revealed thousands of BCFs and bioaccumulation factors (BAFs ) for 842 organic 
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chemicals in 219 aquatic species (Arnot and Gobas 2006). But nearly half of the BCFs had major 
sources of uncertainty, and predicted values that usually underestimated empirical values, which 
were sparse. BAFs under ambient field conditions were generally higher than BCFs obtained under 
controlled conditions. None of these data, however, included APIs. 
Ankley et al. (2005) point out that routine aquatic bioconcentration testing is not common, as 
conventional APIs tend to be water soluble, with Kow values below 3. Even then, higher molecular 
weights (MWs) or a propensity for facile transformation (e.g., via hydrolysis) often preclude biocon-
centration. On the other hand, given the fact that APIs often rely on active transport for uptake (e.g., 
Van Bambeke et al. 2000), even low Ko" values sometimes may not preclude bioconcentration. A 
significant aspect of APIs to note is that they are designed to minimize accumulation in the body 
during intended use, so any build-up that might occur in aquatic tissue could prove toxicologi-
cally significant. Another factor that sets APIs apart from conventional POPs is their metabolism-
sometimes yielding products that themselves can bioconcentrate. This creates the need to calculate 
"pseudo" BCFs-the ratio of tissue concentration of a metabolite and the aqueous concentration of 
the parent API (such as for norfluoxetine). 
Van der Oost et al. (2003) also stress that predicting bioaccumulation in fish using simple models 
(e.g., relying on ~w) is "virtually impossible" and extremely prone to error even with sophisti-
cated models. The dynamics imposed on APIs by pharmacokinetics in particular make prediction 
extremely difficult to model. 
In the absence of empirical data, computed BCFs (e.g., using Quantitative Structure Activity 
Relationship-QSAR-calculations) are often relied upon-at least to try and inform which APIs 
might be of concern with regard to bioconcentration. But this approach has major unknowns with 
respect to pharmaceuticals (Walkeret al. 2004a, 2004b). Other approaches for prioritizing which APIs 
might be of highest exposure concern include those that rely on informatics (e.g., Gunnarsson et al. 
2008, Kostich and Lazorchak 2008) or water/sediment monitoring (e.g., Lissemore et al. 2006). 
Cunningham et al. (2009) reported on calculated BCFs in fish for 43 APIs. They range up to 
highs of 353 Llkg (atovaquone), 190 (dutasteride), 64 (beclomethasone), and 51 (nabumetone), but 
nearly all of the remainder were less than 4 Llkg. In a major analysis of the factors involved with 
bioconcentration, Geyer et al. (2000) provide calculated Kow values or BCFs for a number of natural 
and synthetic estrogens and estrogenic chemicals, androgenic steroids, and nonsteroidal antiandro-
genic chemicals. Quite a number of computed BCFs are mentioned by Grung et al. (2007), and a 
number of computed BCFs for lipid-regulators are provided by Hernando et al. (2007). Other pre-
dictive modeling approaches are explored in Section 8.4. 
The many variables and pitfalls in determining BCFs and their use for predicting BAFs are 
discussed by Parkerton et al. (2008). These issues, which surround the soundness or quality of 
BCF/BAF data, were not evaluated in the summary of published data reported in this chapter. 
8.2.6 OVERVIEW OF FISH TISSUE AND OTHER RESIDUE DATA FOR APls 
The study of the exposure of fish to APIs is dominated by endocrine-disrupting compounds [EDCs; 
predominately by the natural and synthetic estrogenic sex steroids-primarily I7 ,B-estradiol (E2) 
and EE2; comparatively less focus is directed at androgens] and by antibiotics and biocides (such 
as triclosan). Comparatively few data exist for other drug classes. Most studies regarding EDCs 
obviously concern reproductive and other direct endocrine effects. Little exists on exposure to APIs 
having the potential to lead to subtle, difficult-to-detect effects such as alteration of behavior or 
perturbations of the immune system (e.g., Hoeger et al. 2005, Salo et al. 2007). 
Exposure studies regarding endocrine disruption have been dominated by the numerous stud-
ies demonstrating that fish are impacted by exposures to treated and untreated sewage. The first of 
these. which linked exposure to sewage with estrogenicity, was published in 1994 (Purdom et al. 
1994). Most evidence for exposure is inferential. Few studies have established the possibility of 
exposure to either individual or combinations of specific API EDCs. 
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Excluding the data collected on fish uptake of antibiotics as a direct or indirect result of usage in 
aquaculture, actual empirical data are rare for fish-tissue residues of APIs resulting from exposures 
in the environment or exposures under controlled conditions emulating ambient concentrations. 
Determination of empirical BCFs is rarer yet. These data come from two major categories: (1) fish 
collected from (or caged in) wild, native environments and (2) fish exposed under controlled condi-
tions in the laboratory. Collectively, these data exist only for about 30 different APIs, some of which 
were the subject for just a single study (Ramirez et al. 2007). 
The limited data on residue levels from exposure in the natural environment are extremely lim-
ited, primarily comprising: SSRIs (especially paroxetine, fiuoxetine, sertraline, and some principal 
metabolites such as norfiuoxetine and norsertraline), NSAIDs (diclofenac, naproxen, ketoprofen, 
and ibuprofen), steroids (estrone [EI], E2, and EE2), and diphenhydramine, diltiazem, gemfibrozil, 
and carbamazepine (CBZ). Also available are data for biocides (triclosan, methyl triclosan, and 
triclocarban) and malachite green and its leuco metabolite. 
Tissue residue levels resulting from exposures under controlled conditions are a bit more 
common, including many of the same ones as detected under environmental monitoring, but also 
including: ,B-blockers (propranolol and atenolol), fungicides (the triazoles: bromuconazole, cypro-
conazole, metconazole, myclobutanil, penconazole, propiconazole, tebuconazole, tetraconazole, 
and triadimefon), the macrocyclic lactone avermectin Bl, steroids (hydroxyestrone, estriol [E3], 
17,B-dihydroequilenin, and testosterone), and mono- and di-brominated derivatives of EE2. 
These data are discussed in more detail in the succeeding sections. While on the one hand it is 
interesting that most of these APIs have BCFs greater than unity (considering their generally low 
Kow values), few have BCFs above 1000 and therefore do not have anywhere near the accumula-
tion potential of the POPs. The tissue levels of low-Kow APIs point to uptake mechanisms beyond 
passive diffusion. The greatest concentrations tend to be in the bile and liver. Actual bioconcen-
tration of diclofenac seems to be higher than for most APIs. The computed BCF for fiuvastatin 
is among one of the highest for any API. But the highest measured BCFs are for the biocide 
triclosan, which was found to range upward of 10,000 in the intestines of zebra fish (Orvos et al. 
2002). The most empirical data exist for steroids and antibiotics. While residues in edible tis-
sues have clear ramifications for human exposure, residues in organs such as the brain (a focus 
for monitoring targeted at SSRIs) have implications regarding immediate biological effects. All 
residues have implications with respect to trophic biomagnification, which has not been studied 
with respect to APIs. 
8.2.6.1 SSRls/SNRls (Selective Serotonin and Serotonin-Norepinephrine 
Reuptake Inhibitors) 
Fluoxetine and sertraline and their principal metabolites (norfiuoxetine and norsertraline) were 
detected in all fish tissues (brain, liver, and muscle) from three fish species collected from Pecan 
Creek TX, an effluent-dominated stream: Lepomis macrochirus (bluegill), Ictalurus punctatus 
(channel catfish), and Pomoxis nigromaculatus (black crappie) (Brooks et al. 2005). All four 
analytes were detected in all tissues at levels exceeding 0.1 ng/g; no residues were detected in 
fish from a reference site not receiving effluent discharges. Compared with average tissue levels 
of fiuoxetine and sertraline, the average levels for norfiuoxetine and norsertraline were higher 
in brain, liver, and muscle. The highest concentrations for each API were detected in the brain, 
generally followed by the liver: norsertraline (15.6 and 12.94 ng/g), norfiuoxetine (8.86 and 10.27 
ng/g), sertraline (4.27 and 3.59 ng/g), and fiuoxetine (1.58 and 1.34 ng/g); the lowest concentra-
tions were in muscle: norfiuoxetine (1.07 ng/g), norsertraline (0.69 ng/g), sertraline (0.34 ng/g), 
and fiuoxetine (0.11 ng/g). These levels are roughly 0-4 orders of magnitude higher than reported 
in wastewater and effluent-dominated streams, refiecting bioconcentration as well as the possi-
bility of active transport. Although hypothetical human dietary exposure from these fish would 
yield daily intakes roughly 6 orders of magnitude below therapeutic doses, note that ADIs exist 
only for veterinary drugs. 
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Schultz et a1. (2010) recently reported extensive data from a monitoring study involving the 
largest suite of APIs yet targeted from any single therapeutic class (SSRIs/SNRIs); they also col-
lected concomitant data from three matrices (water, bed sediment, and brain tissue of white sucker, 
Catostomus commersoni) from two effluent-impacted streams in Iowa and Colorado. They targeted 
JO antidepressants (including two metabolic/transformation products): bupropion, citalopram, 
duloxetine, fluoxetine (and norfluoxetine), fluvoxamine, paroxetine, sertraline (and norsertraline), 
and venlafaxine, an SNRI. All but two (duloxetine and fluvoxamine) were found in brain tissue. 
Of particular interest was the distinct lack of correlation between the types and quantities of these 
APls measured in the stream waters versus those in the brain tissues. Venlafaxine was found in 
most of the stream samples at concentrations consistently higher than the next two most prevalent 
(bupropion and citalopram), sometimes at levels over an order of magnitude higher. The levels 
of venlafaxine in the streams sometimes exceeded 0.5 Ilg/L. In contrast, the primary analytes in 
brain tissue were norsertraline and sertraline, followed by norfluoxetine and fluoxetine. Indeed little 
venlafaxine, bupropion, or citalopram were found in brain tissue but were prevalent in sediments 
(although their relative levels were generally the inverse of those in brain tissue). These data point to 
the possible involvement of selective uptake of these chemicals into brain tissue. The maximum and 
the range of mean concentrations (ng/g) in brain tissue were: norsertraline (28.9; 0.01-3), sertraline 
(4.24; 0.005-1.8), norfluoxetine (3.57; 0.07-0.9), and fluoxetine (1.65; 0.02-0.6). The maximum 
level reported for norsertraline (28.9 ng/g) is the highest yet reported for an API in brain tissue. 
In a more recent study, Brooks et al. (in preparation) observed sertraline, norsertraline, flu ox-
etine, and norfluoxetine at low ng/g levels in periphyton and three taxa of benthic macroinverte-
brates (Corbiculajluminea, Argia sp., hydropsychidae) collected from Pecan Creek TX, indicating 
that dietary exposure to fish from these SSRls and potentially other APTs deserve further study. As 
noted elsewhere in this document, extraction and analysis approaches to account for matrix differ-
ences among aquatic organisms require further development. For example, a recent study advanced 
extraction techniques for identification of APTs in mollusks (Cueva-Mestanza et a1. 2008). 
Fish from a Lake Ontario harbor receiving sewage effluent were analyzed for SSRIs by Chu and 
Metcalfe (2007). Seven fish were collected from three species [three brownbullhead (Ameiurus 
nebu/osus), three gizzard shad (Dorosoma cepedianum), and one white perch (Morone ameri-
cana)1 and analyzed for paroxetine, fluoxetine, and norfluoxetine. Concentrations on the basis of 
whole wet weight ranged up to 1 Ilg/kg: paroxetine (0.48-0.58 Ilg/kg; 3 of 7 samples), fluoxetine 
(0.14-1.02 Ilg/kg; 6 of 7 samples), and norfluoxetine (0.15-1.08 Ilg/kg; 4 of 7 samples); neither 
fluoxetine nor norfluoxetine was detected in white perch. This occurrence of paroxetine is the first 
reported in the literature. 
In a 2-year study in the Caloosahatchee River, Florida, water samples and the plasma of juve-
nile bull sharks (Carcharhinus leucas) were analyzed for four SSRIs and a metabolite (citalopram, 
fluoxetine/norfluoxetine, paroxetine, and sertraline) and an SNRI (venlafaxine) (Gelsleichter 2009). 
Only citalopram, sertraJine, and venlafaxine were detected in wastewater or river-water samples. 
All analytes except for fluoxetine, however, could be detected at very low quantifiable levels in at 
least one plasma sample from at least one of the 2 years. Sertraline was the only analyte detected in 
all samples in 2006, while only venlafaxine and citalopram were detectable in 2007. 
The bioconcentration of fluoxetine at an exposure concentration of 10 Ilg/L by Japanese medaka 
(Oryzias lalipes) was evaluated under controlled conditions, at three pH values below the pKa 
(Nakamura et al. 2008). The empirical BCFs were 8.8, 30, and 260 for the body and 330, 580, 
and 3100 for the liver, at respective pH values of 7, 8, and 9; the BCF for fluoxetine summed 
over the body and liver was 11 at pH 7.2. The BCFs increased with increasing pH since fluoxetine 
is a weak base and uptake of the nonionized molecule is facilitated by diffusion. Not unexpect-
edly, the N-demethylated metabolite norfluoxetine was similarly recovered. BCFs predicted from 
liposome/water equilibration did not increase as much with increasing pH as did BCFs predicted 
by octanollwater partitioning (with control of ionic strength). Bioconcentration of an API such as 
fluoxetine, while made complicated by pH influencing ionization, differs dramatically from the 
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bioconcentration of a conventional, long-lived POP. It is further complicated when the API (such as 
f1uoxetine) can be metabolized to another chemical species (in this case, norfluoxetine) that is also 
subject to bioconcentration. Since S-norfluoxetine binds to the serotonin reuptake transporter with 
affinity similar to that of R-f1uoxetine and S-f1uoxetine (Wong et al. 1993), the combined sum of the 
parent compound and active metabolite should be considered in determining bioconcentration and 
effects in ecological risk assessment. 
Using caged fathead minnows in the outfall from sewage treatment plants, Metcalfe et al. (2010) 
detected venlafaxine, citalopram, sertraline, and a demethylated metabolite from each (as well as 
norfluoxetine) at levels roughly ranging from 1 to 4 ng/g (whole-body wet weight). Only sertraline, 
however, was detected in more than one of the three sites examined. 
Research on the pharmacokinetics of APIs in fish is very sparse. Schultz et al. (2001) published 
perhaps the first study-on 17a-ethinylestradiol. Paterson and Metcalfe (2008) published an initial 
examination of the uptake and elimination of f1uoxetine. At the outset of exposure to 0.55 f./g/L in 
water over 7 days, accumulation by medaka was noted within the first 5 h; norfluoxetine was also 
noted at this time at about 40% of the f1uoxetine level. A peak tissue concentration of 49 f./g/kg was 
recorded after 3 days for f1uoxetine. After 6 days, norfluoxetine exceeded f1uoxetine: 64 f./g/kg ver-
sus 40 f./g/kg. This yielded a BCF of 74 for f1uoxetine and a pseudo-BCF of 117 for norfluoxetine. 
These studies (Brooks et al. 2005, Chu and Metcalfe 2007, Nakamura et al. 2008, Paterson and 
Metcalfe 2008, Schultz et al. 2010) collectively show that an API metabolite (such as norfluoxetine) 
can accumulate to equal or greater tissue concentrations than its parent (e.g., f1uoxetine), which is 
not surprising since norfluoxetine is more nonpolar than f1uoxetine. This is important when the 
metabolite (such as norfluoxetine) is bioactive. Metabolic conversion of the parent API means that 
its measured BCF will be lower than its actual BCF. Presence of an API in tissue might serve as an 
indicator of higher exposure to a metabolite of similar or higher biological activity. Whether these 
residues are bioavailable, however, is a key question, as shown by Zhou et al. (2008) who reported 
that the BCFs for "free" (unbound and directly bioavailable) f1uoxetine were less than unity, while 
those for total f1uoxetine were in the range reported by these previous studies. It is also not always 
clear whether API metabolites in tissues result from endogenous metabolism or from uptake of pre-
existing metabolites from water. 
Clearly, the relationship between coexposure to SSRIs/SNRIs, tissue residues, and potential bio-
logical effects requires further study. This was highlighted by the recent work of Painter et al. 
(2009), which identified environmentally relevant concentrations of a mixture of SSRIs/SNRIs to 
adversely affect fathead minnow predator escape behavior. 
8.2.6.2 NSAIDs (Nonsteroidal Anti-inflammatory Drugs) 
Given the widespread usage of NSAIDs and the published data on their environmental occur-
rence and ecotoxicology, surprisingly few studies have monitored for any of the NSAIDs in aquatic 
organisms. 
Brown et al. (2007) exposed caged juvenile rainbow trout to sewage effluent at three sites and 
measured plasma levels for various NSAIDs (and gemfibrozil). This was the first reported mea-
surement of fish plasma levels of diclofenac, naproxen, and ketoprofen (as well as gemfibrozil) 
after exposure in the field. All except ketoprofen showed a propensity to bioconcentrate in plasma. 
Plasma concentrations ranged from tens to several thousand ng/mL, with the highest being for 
gemfibrozil. Of particular significance was the wide range of BCFs for any particular API across 
the study sites. The wide variance in BCFs did not seem to be a function of API concentration in the 
water, temperature, pH, or exposure time; the authors concluded that some other chemical charac-
teristic of the effluents governed uptake, possibly the presence of colloids or surfactants. Compared 
with predicted BCFs, all of the APIs, with the exception of ibuprofen, had BCFs that ranged from 
unity to considerably lower. 
Under static exposure to high nominal concentrations (490~1000 f./g/L) , plasma levels ranged 
from: 60 ng/mL (ketoprofen), 3440 (diclofenac), and 3640 (naproxen), to 4680 (ibuprofen); under the 
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same conditions, the level for gemfibrozil was 21,500. These gave empirical BCFs ranging from: 0.1 
(ketoprofen),4 (naproxen), 7 (diclofenac), to 9 (ibuprofen) [and 63 for gemfibrozil]. 
During the caged study, the exposure levels at the three sites ranged from 4.5 ng/L (ibuprofen) 
to 2320 ng/L (diclofenac). Resulting plasma concentrations ranged from undetectable (ketoprofen), 
12 ng/mL (diclofenac), 14 (naproxen), and 84 (ibuprofen) (and 210 for gemfibrozil). These gave 
BCFs ranging from: <11 (ketoprofen), 5 (diclofenac), 56 (naproxen), to 18,667 (ibuprofen) (and 199 
gemfibrozil). 
With juvenile rainbow trout exposed under continuous flow for 96 h to 920 fJg/L ibuprofen, after 
the first 24 h of exposure, the plasma concentrations of ibuprofen increased, beginning at about 
7 fJg/mL and ending at about 10.6 fJg/mL (Huggett et al. 2004), in rough agreement with the data 
from Brown et al. (2007). 
The bioconcentration of diclofenac by fish was reported for the first time by Schwaiger et al. 
(2004). Rainbow trout (Oncorhynchus mykiss) were exposed for 28 days to concentrations ranging 
from I to 500 fJg/L. Concentrations in the liver were about 40-fold greater than in muscle. With 
exposure to 1 fJg/L, tissue residue concentrations were about: 2882 ng/g (liver), 1025 ng/g (kid-
ney), 805 ng/g (gills), and 73 ng/g (muscle), yielding BCFs (Llkg) of 2732 (liver), 971 (kidney),763 
(gills), and 69 (muscle); plasma levels were not reported. Tissue concentrations increased linearly 
with increasing dose, up to 500 fJg/L, which yielded tissue concentrations roughly twice those from 
the l-fJg/L dose. The lower tissue concentrations with respect to dose are the reason the calculated 
BCFs decreased with increasing concentrations. 
Mehinto (2010) reported bile BCFs in the narrow range 509-657 after 21-day exposures of trout 
to diclofenac at 0.5, 5.0, and 25 ng/L. 
8.2.6.3 Lipid Regulators 
Gemtibrozil was shown to bioconcentrate in the plasma of goldfish (Carassius auratus) after labora-
tory exposure to an environmentally relevant concentration of 0.34 fJg/L (nominal 1.5), as well as a 
higher concentration of 852 fJg/L (nominal 1500) (Mimeault et al. 2005). After 14 days of exposure, 
plasma BCFs were 500 and 92, respectively, resulting from respective plasma concentrations of 
roughly 170 and 78,000 fJg/L. Uptake was concluded to occur across the gill membrane but passive 
diffusion or active transport could not be distinguished. 
In the same study with four NSAIDs, gemfibrozil was measured in the plasma from rainbow trout 
caged in effluent-dominated streams and during a controlled static exposure experiment (Brown 
et al. 2007). This was the first measurement of a fish plasma level of gemfibrozil after ambient expo-
sure in the field. Of the five APls, the resulting plasma levels were highest for gemfibrozil. Static 
exposure to a high level of 510 fJg/L gave a plasma level of 21,500 ng/mL, yielding a BCF of 63. In 
the caged field study, the plasma level reached 210 ng/mL, yielding a BCF of 199. 
A compendium of calculated Kow and BCF values for a number of fi brates and statins is provided 
by Hernando et al. (2007). While the 10gKow values all indicate relatively high Iipophilicity (most 
exceeding 4), computational approaches for estimating BCFs showed relatively low values (3.2) 
for bezatibrate, gemfibrozil, clofibric acid, fenofibric acid, and pravastatin, and 56 for atorvastatin; 
values ranged from 120 to 380 for clofibrate, fenotibrate, lovastatin, and mevastatin. Higher com-
puted values were found only for simvastatin (800) and fluvastatin (2000). These values might be 
useful for targeting these latter two statins for biomonitoring to determine actual empirical BCFs. 
Note, however, that the low computed BCF for gemfibrozil is not predictive of the empirical BCFs, 
being 1-2 orders of magnitude lower than those measured by Mimeault et al. (2005) and Brown 
et al. (2007). 
8.2.6.4 fl-Blockers 
Owen et al. (2007; also unpublished data; Owen et al. 2009) exposed juvenile rainbow trout to rela-
tively high levels of propranolol: 10 mg/L for 10 days. Plasma levels of about 5 fJg/mL were reached; 
concentrations were often 40-80% of the water levels after 40 days. 
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Winter et al. (2008) exposed fathead minnows to relatively high concentrations (0.1-10 mg/L) 
of atenolol. Compared with water concentrations, plasma concentrations ranged between 1.8% and 
6.2% (for males) and 0% and 12.2% (females). The male fish plasma concentration for atenolol 
corresponding to the exposure concentration for the LOEC (Lowest observed effect concentration) 
condition index (3.2 mg/L) was 0.0518 mg/L (51 Ilg/mL). 
Cleuvers (2005) reported calculated BCFs of 4.47 and 0.89 for propranolol and metoprolol, and 
a value for atenolol too low to calculate. But ,B-blockers were not detected in fish during a study by 
Brooks et al. (2005, unpublished data). 
8.2.6.5 Fungicides 
Juvenile rainbow trout (0. mykiss) were exposed to nine triazole fungicides (dual-use pesticides 
and pharmaceuticals) in feed containing each at 23-35 flg/g (wet weight) (Konwick et al. 2006). 
These triazoles had log Kow's ranging from 2.9 to 3.9: bromuconazole, cyproconazole, metcon-
azole, myclobutanil, penconazole, propiconazole, tebuconazole, tetraconazole, and triadimefon. 
Each compound was taken up quickly, reaching steady state after a day of exposure. They quickly 
reached concentrations in body lipids ranging from roughly 0.5-1 flg/g lipid, yielding biomagni-
fication factors (on the basis of lipid content of fish vs. lipid content of food) ranging from 0.006 
(propiconazole) to 0.012 (triadimefon and tebuconazole). 
8.2.6.6 Macrocyclic Lactones 
The macro-lactone dual-use parasiticides (used in veterinary medicine) are best known as the aver-
mectins. Examples of these large, polycyclic lactones include: abamectin, albendazole, doramectin, 
emamectin, eprinomectin, ivermectin, morantel, moxidectin, milbemycin, and selamectin. Residues 
are well-established as occurring primarily in liver and lipid tissues, followed by kidney and muscle. 
An overview of this chemical class is provided by Danaher et al. (2006). Escher et al. (2007) point 
out that uptake kinetics and calculated BCFs are lower than predicted based on hydrophobicity. This 
is hypothesized to result from membrane exclusion because of the large molecular cross section. 
Avermectin BI (abamectin) was shown to resist uptake by sturgeon (into muscle) (Shen et al. 
2005); biomagnification therefore would not occur. After a 22-day exposure to 0.2 and I ng/mL in 
water, concentrations in muscle reached steady state in about 2 weeks, giving muscle concentrations 
of 7.75 and 38.29 ng/g, respectively, yielding BCFs of 41-42. 
Exposure for 28 days of bluegill sunfish (L. macrochirus) to an aqueous concentration of 
0.099 flg/L avermectin Bla gave tissue concentrations of 6.8, 3.0, and II flg/kg, in whole fish, 
fillet, and viscera, respectively, yielding BCFs of 56,28, and 84 (Van den Heuvel et al. 1996). As 
with other studies, it was concluded that abamectin does not strongly bioconcentrate and would 
therefore not be expected to biomagnify. 
8.2.6.7 Steroids 
Determining the uptake and bioconcentration of steroids is complicated by the fact that many of 
them have multiple origins. Several of the estrogens, for example, are endogenous to all fish (and 
some invertebrates but not plankton). Endogenous production can be further complicated by sub-
stances that induce synthesis (e.g., via aromatization) or inhibit excretion (e.g., repression of efflux 
pumps). But they also have at least two other origins. The first is the subject of this chapter-many 
have origins from the pharmaceutical preparations in which they are used; even ,B-estradiol is used 
in certain hormone preparations. The second origin is from other fish, which excrete a variety of 
steroids, for example as pheromones (Scott and Ellis 2007). These origins become intermingled 
with that resulting from endogenous synthesis; for estrogens and androgens, this becomes problem-
atic for modeling female and male fish, respectively. 
The steroids are also intimately involved in a metabolic cascade that involves interconversion, 
such as via aromatization, and conjugation. Uptake from surrounding media continually adds to 
the pool involved with natural metabolic processes. These factors greatly complicate the modeling 
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of uptake and bioconcentration. Given the dynamic state of uptake, interconversion, and excretion, 
steady-state concentrations are probably rarely reached in laboratory studies; life-cycle studies are 
rare. This leads to very wide ranges in both predicted and measured tissue concentrations and 
BCFs-measured both under controlled laboratory conditions and in the wild. An overview of the 
environmental occurrence and consequences of exposure of fish to natural and synthetic estrogenic 
chemicals (of which only a small portion are APIs) is provided by Tyler et al. (200S); further discus-
sion on bioaccumulation of E2 and EE2 is provided by Langston et al. (200S). A method using gas 
chromatography/mass spectrometry was developed for simultaneously quantifying 12 endogenous 
steroids in plasma and bile, using flounders (Platichthys fiesus) as the test species (Budzinski et al. 
2006); the steroid analytes spanned the estrogen/androgen metabolic cascades from pregnenolone 
and progesterone to E2 and ll-ketotestosterone. 
One major but very limited source of data on uptake and tissue levels of estrogenic and androgenic 
steroids is from the aquaculture literature. Steroids are used to induce sex reversal in farmed popula-
tions. These data are not covered here. The data of Stewart et al. (2001) serve as one example. 
Rainbow trout (0. mykiss) and roach (Rutilus rutilus) exposed to treated sewage effluent in 
controlled continuous-flow tanks concentrated El, E2, and EE2 in the bile-at levels beyond 
endogenous production (Gibson et al. 200Sa, 200Sb). Most was present as glucuronide conjugates. 
Bioconcentration was roughly 4000-6000 for EE2 and 10,000-13,000 for E2 and El combined. The 
conjugated equine estrogen (CEE) metabolite, 17,B-dihydroequilenin (17,B-Eqn), was also detected; 
while this is perhaps the first report of 17 ,B-Eqn in an aquatic organism (or in any environmental 
sample), its specific source was unknown (e.g., whether an endogenous metabolic product vs. an 
ingredient from a conjugated equine hormone preparation). 
This work on CEEs (Gibson et al. 200Sa) was extended further in a comprehensive examina-
tion of treated and untreated sewage and fish exposed under controlled conditions (Tyler et al. 
2009). Treated sewage from wastewater treatment plants (WWTPs) in the United Kingdom 
were examined for six CEEs: equilin (Eq) and equilenin (Eqn), and four metabolites, 17,B-
dihydroequilin (17,B-Eq), 17 a-dihydroequilin (17 a-Eq), 17,B-dihydroequilenin (17 ,B-Eqn), and 
17a-dihydroequilenin (17a-Eqn). The bile from two species of fish (rainbow trout and the com-
mon carp, Cyprinus carpio) exposed to treated sewage effluent was also analyzed. Among these 
six CEEs, only two (Eqn and its metabolite 17,B-Eqn) were detected in wastewaters. Eqn con-
centrations ranged from 1.32 to 2.S9 ng/L (influent) and 0.32-1.32 ng/L (effluent), and 17,B-Eqn 
ranged from <0.2 (LOD) to 0.37 ng/L (influent) and 0.07-0.1S ng/L (effluent), concentrations on 
par with those of E2 and EE2. The authors pointed out that since these two CEEs occurred in 
sewage influent, their origin from hormone replacement products was more probable than from 
exogenous metabolic processes. 17,B-Eqn (as in the prior study) and now Eqn (for the first time) 
were the only two CEEs detected in bile. BCFs for trout exposed to 17,B-Eqn were calculated to 
be 1.S x 106 and 2.2 x 106 for trout exposed to Eqn. 
Notably, the study of Tyler et al. (2009) is one of the very few focusing on aquatic exposure to 
also extend its findings to the potential for effects from exposure to environmentally realistic con-
centrations. Concentrations of 17 ,B-Eqn as low as 0.6 ng/L elicited a vitellogenic response in trout, 
as well as all but the lowest exposure concentration of Eqn (4.2 ng/L); the carp were nearly three 
orders of magnitude less sensitive. A 17,B-Eqn concentration of 0.6 ng/L nearly intersects with its 
concentrations detected in the treated UK wastewaters, providing a rare linkage between real-world 
exposure levels and the potential for adverse effects. 
The difficulty in tying exposure to effects is demonstrated in another unique study, involving 
fish showing signs of possible exposure to estrogens. Three separate projects involved male bream 
(Abramis brama) with ovotestis and vitellogenin from two different locations in the Netherlands 
and whitefish (Coregonus lavaretus) with malformed gonads from Lake Thun, Switzerland 
(Vogeli 200S). In the ovotestis case, while levels of EI, E2, and EE2 in adipose tissue did not dif-
fer from controls, levels of EI and EE2 in bile showed bioaccumulation in the ovotestis fish; E2 
did not differ from the control. In contrast, with the case of elevated vitellogenin, levels of El, E2, 
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and EE2 were higher in the bile of the controls. With the group with malformed gonads, only El 
and E2 were present (above the MDLs) in the bile of all fish but the levels were higher in the fish 
with normal gonads. 
In male Rainbow trout exposed to EE2 at relatively high nominal water levels of 125 ng/L, EE2 
was shown to be rapidly absorbed (Skillman et al. 2006). EE2 was detected in plasma upon the first 
sampling time of 15 min and reached a steady-state range of 60-90 ng/mL within 16 h, yielding a 
BCF of up to 720. Levels in the liver corresponded with those in the plasma. In the bile, levels of 
free EE2 were also similar to those of the plasma and liver. In the bile, however, conjugated EE2 
continued to increase, until 99% of the total EE2 in the bile comprised conjugated glucuronides. 
The authors conclude that EE2 in plasma, reaching equilibrium levels several hundred-fold higher 
than in water, represents a viable means for measuring current environmental levels; bile levels, 
in contrast, were more representative of cumulative exposure. The study also followed the parallel 
time course synthesis of vitellogenin and gene expression. 
A model developed by Lai et al. (2002b) predicted relative bioconcentration of steroids, ranging 
from fish at the highest trophic level (1.8 for E3) to fish at the lowest trophic level (332 for EE2). 
In another study (Lai et al. 2002a) examined the uptake of natural (El, E2, hydroxyestrone, and 
E3) and synthetic (EE2 and estradiol valerate) estrogens by the freshwater alga, Chiarella vulga-
ris. Under static conditions, all the estrogens were taken up, but E3, hydroxyestrone, E2, and EE2 
could not be detected, because of metabolism. No equilibria could be reached, except for El, for 
which a BCF of about 27 was calculated. On the basis of Kow' EE2 would be expected to accumu-
late more, but did not-possibly because of active transport of the endogenous estrogens or active 
efflux of EE2. 
Juvenile rainbow trout (0. mykiss), under controlled conditions, were exposed to sewage under 
continuous flow before and after treatment by sand filtration (Pettersson et al. 2006). After 28 days, 
bile was sampled. When exposed to untreated water, levels of El were two orders of magnitude 
higher than in controls (4.0 f./g/g vs. 0.04 f./g/g). Bile levels were also higher compared with controls 
for EE2 (0.25 f./g/g vs. 0.10 f./g/g) and E2 (0.17 f./g/g vs. 0.04 f./g/g). When exposed to treated water 
(posts and filtration), the bile concentrations for El (0.17 f./g/g) and E2 (0.04 f./g/g) were reduced 
considerably. The concentration for EE2, however, was slightly higher (0.38 f./g/g). 
In a subsequent study, Pettersson et al. (2007) examined the bile of perch (Perea fiuviatilis L.) 
from the coastal waters of the Swedish Baltic Sea impacted by sewage for El, E2, and EE2. Studies 
of fish from the wild are uncommon. EE2 was never detected, in contrast with El and E2, which 
were almost always present. These levels did not differ significantly from samples obtained from 
reference sites. These findings, however, corroborated lack of signs of endocrine effects, possibly 
because of efficient sewage treatment practices. 
In another study using fish in the native ambient environment, Vermeirssen et al. (2005) used 
caged brown trout downstream of sewage effluents at five sampling sites. They measured E2, El, 
and EE2 but did not report them separately-only as estradiol equivalents. Houtman et al. (2004) 
also indirectly measured EE2 via estrogen assay (in the bile of male bream, A. brama). 
In a study of juvenile bull sharks (c. leueas) in the Caloosahatchee River, Florida, EE2 was 
detected in plasma at levels only up to slightly above the MDL (Gelsleichter 2009). EE2 was detected 
only during the second of 2 years of sampling (2006-2007), being detected in 7 of the 12 sharks 
sampled; EE2 was not detected in the Myakka River, a control river that did not receive treated 
wastewater. Levels of EE2 in the river ranged only up to 0.23 ng/L. Of the seven shark plasma sam-
ples with detectable residues, the two that could be quantified ranged up to 3.79 ng/mL plasma. 
Perhaps the first bioconcentration study of EE2 in fish was reported by Larsson et al. (1999). 
Caged juvenile rainbow trout (0. mykiss) were exposed to an effluent-dominated stream, and El, 
E2, and EE2 were measured in bile. The respective concentrations (conjugated and unconjugated 
combined) for El, E2, and EE2 in the bile after 2 and 4 weeks were (approximately): 0.6 and 2.5 
f./g/g; ND and 1.0 f./g/g; and 0.3 and l.l f./g/g. These bile concentrations of roughly 1 ppm were about 
4-6 orders of magnitude higher than the water levels. A separate static study using juvenile rainbow 
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trout exposed for 46 h to 5 iJg/L of either El, E2, or EE2 produced respective bile concentrations of 
>400, -200, and -350 iJg/g. 
Perhaps the first full life-cycle bioconcentration study of EE2 in fish was reported by Lange et al. 
(2001). A life-cycle exposure study, using the fathead minnow (Pimephales promelas) was done 
using newly fertilized embryos (24-h old) under continuous flow for 305 days at five concentrations 
of EE2: 0.2, 1.0,4.0, 16, and 64 ng/L (Lange et al. 2001); note that the two highest concentrations 
were toxic. No EE2 could be detected in tissue «0.38 ng/g) after exposure at 0.2 and 1.0 ng/L test 
concentrations 192 days posthatch. At 16 ng/L (239 days posthatch) and 64 ng/L (153 days post-
hatch), the EE2 tissue levels were 7.3 and 31 ng/g, yielding BCFs of 610 and 660, respectively. The 
authors concluded that the BCF (L/kg) was likely less than 500 (and probably less than 2400) for 
healthy fish. A more recent study by Caldwell et al. (2008) provided an HC5 value (hazardous con-
centration predicted to negatively affect 5% of the population) of 0.343 ng/L for a species sensitivity 
distribution (SSD) of EE2, highlighting the high potency of this API. 
The bioconcentration of steroids is yet further complicated by the possibility that uptake is being 
augmented by facilitated transport to yield tissue levels far beyond what would be predicted with 
existing models assuming passive brachial uptake. 
A study using the three-spined stickleback (Gasterosteus aculeatus) used 6-day static exposure 
concentrations of I iJg/L (nominal) of either E2, testosterone (T), or E2 and T combined (Maunder 
et al. 2007). Plasma levels climbed rapidly within the first 6 h to within the range of 20-90 ng/mL. 
These bioconcentrated levels were 50-fold (E2) and 200-fold (T) greater than the measured expo-
sure concentrations. The authors postulated that the faster and greater uptake than predicted of E2 
and T might be due to the presence of a plasma sex hormone-binding globulin (SHBG). Scott et al. 
(2005) also postulated that SHBG is responsible for enhanced uptake of many of the steroids. This 
hypothesis is set forth in more detail by Miguel-Queralt and Hammond (2008). 
Miguel-Queralt and Hammond (2008) report that natural and synthetic estrogens and androgens 
are actively taken up by fish via the gills by way of binding to SHBG in the brachial filaments. This 
uptake mechanism is extremely fast, with up to 70% of T or EE2 being removed from water in 90 
min. A broad range of steroids have a high affinity for fish SHBG, whose ligand specificity varies 
widely across species. Trace amounts (e.g., 50 pmol) of ligand can be taken up from water within 
minutes. After uptake, residues are rapidly distributed throughout the body; EE2 was reported to then 
accumulate in the brain, ovaries/eggs, and muscle. The authors point out that SHBG also has a high 
affinity for at least two of the more common progestin APIs-levonorgestrel and 19-norethindrone. 
Since these APls may be frequently present in sewage-derived waters, sometimes at relatively high 
concentrations, this points to the possibility of progestins occurring in fish. Progestins, however, have 
only rarely been targeted in environmental monitoring. Sediments in Puget Sound were analyzed for 
the synthetic progestogen 19-norethindrone. Levels ranged from 419 to 890 ng/g, but the analysis was 
done with GC-FlD rather than GC-MS (Kimball 2008). 19-Norethindrone was the most frequently 
detected and abundant (26-224 ng/L) of all the synthetic estrogens/progesterones in sewage influent 
samples (Fernandez et al. 2007). Lopez de AIda et ai. (2002) reported 19-norethindrone as frequently 
occurring in sediments but at low ng/g-Ievels. Viglino et al. (2008) reported levonorgestrel and 19-no-
rethindrone concentrations in sewage effluent ranging between 30 and 53 ng/L, respectively. 
Others postulate that steroid residues in food may contribute more to bioaccumulation by fish 
than do the residues at significantly lower concentrations in water. Takahashi et ai. (2003) report E2 
concentrations ranging from 0.0001 to 0.0076 iJg/L in water, compared with 0.09-2.26 iJg/kg-wet 
in the periphytons and less than 0.01-0.22 iJg/kg-wet in the benthos. Bioaccumulation factors of E2 
were estimated at 64-1200 for the periphyton and 100-160 for the benthos. 
It is important to note that even though the BCFs for EE2 do not indicate a propensity for bioac-
cumulation, the extremely low no-effect levels for this steroid have led a number of investigators to 
recommend more detailed examinations (e.g., Lyssimachou and Arukwe 2007). 
Direct uptake from water of El by Daphnia magna gave a BCF of 228 (Gomes et al. 2004); 
biomagnification via feeding on C. vulgaris was not as efficient. 
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In a controlled study using artificial sediment and radiolabeled EE2, a benthic freshwater oli-
gochaete (Lumbriculus variegatus) was exposed over 35 days to a nominal concentration of 300 
ng/g wet-weight sediment (556 ng/g dry weight) (Liebig et al. 2005). Continuous linear uptake 
never reached steady state. The BSAF was 75 after the 35 days. A calculated steady state (after 360 
days of exposure) would yield a BSAF of 190-higher than predicted by Kow. A study with two 
invertebrates-a midge (Chironomus tentans) and amphipod (Hyalella azteca)-followed 21-day 
EE2 exposures using spiked water and water with sediments (Dussault et al. 2009). The exposure 
concentrations, however, ranged up to 3.l ppm, orders of magnitude higher than those found in the 
ambient environment. At one of the lower, but still high, water-only exposures (20 Ilg/L), the BCFs 
were 31 for C. tentans and 142 for H. azteca; BSAFs were 0.8 and l.5, respectively. 
8.2.6.8 Antibiotics: Informing Environmental Exposure with Data 
from Use of Veterinary Aquaculture Drugs 
APIs are used in aquaculture at levels many orders of magnitude higher than their occurrence in the 
ambient environment. Exposure data in aquaculture settings are obtained usually to assess if thera-
peutic or prophylactic doses are reached and to assess subsequent depuration of residues to ensure 
consumer safety. For this reason, the exposure concentrations are orders of magnitude higher than 
ambient levels, and the antibiotics studied tend to be restricted to those used in veterinary practice 
(although use of unapproved, illegal drugs also occurs). An overview of antibiotics used in aquaculture 
is provided by Sapkota et al. (2008). In a Canadian Total Diet Study focused on residues of 39 different 
veterinary drugs, levels tended to be in the range of low nanograms per gram (Tittlemier et al. 2007). 
Even though exposures emulating those during aquaculture occur at higher ambient levels of 
APIs, they might be useful as worst-case scenarios to inform the potential for bioconcentration 
under ambient conditions. As one example, trout raised in aquaculture receiving medicated feed 
with roughly 0.6% oxytetracycline (OTC), which yielded a maximum water concentration of about 
0.8 ppm, reached a maximum muscle-tissue concentration of 1.8 ppm (Bebak-Williams et al. 2002). 
This maximum level rapidly dissipated once the aqueous concentration dissipated. This shows that 
at high exposure concentrations, the muscle-tissue level shows very little bioconcentration. The 
literature on veterinary drug exposure is comparatively large, just two examples being Hou et al. 
(2003) and Chu et al. (2008), who examined the uptake into muscle and depuration of sulfamethaz-
ine and nitrofurans. 
The study of aquatic exposure to APIs actually began several decades ago. The study of antibiot-
ics used in aquaculture led to the need for examining aquatic tissue levels to assess therapeutic dose 
levels while assuring levels were sufficiently low for human consumption via the food supply. But 
even then, the potential for environmental impacts was also a consideration; the early work of Coats 
et al. (1976) using model ecosystems is an example. 
Early studies on the environmental fate and possible biomagnification of veterinary drugs, par-
ticularly parasiticides, antibiotics, and other biocides, began in the 1960s and 1970s. Many of these 
studies were comprehensive and generated considerable data, as they used traditional radiolabeled 
materials to try and reach closure around mass balances. For example, 3-day uptake in fish of four 
veterinary drugs was studied in aquatic model ecosystems, using radiolabeled anthelmintic pheno-
thiazine, the coccidiostat clopidol, the bacteriostat sulfamethazine, and the growth promoter dieth-
ylstilbestrol (Coats et al. 1976). 
Another route of exposure as a result of aquaculture, however, occurs because 70-80% of the 
APIs used in medicated feed are released to the ambient environment as a result of excretion or 
escape by way of feed that is not consumed (Pouliquen et al. 2009). Native fish in the vicinity can 
then be unintentionally exposed-to levels exceeding ambient background concentrations. Usage 
of antibiotics in aquaculture, however, is episodic and occurs for very limited number of days, but 
concentrations in sediments immediately below can exceed the ppm-level (Pouliquen et al. 2009). 
Samuelson et al. (1992) reported that levels of several antibiotics in aquatic organisms nearby aqua-
culture exceeded levels considered safe for human consumption; also see Cabello (2006). 
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Blue mussels (Mytilus edulis) were evaluated for their ability to bioconcentrate two veterinary 
antibiotics: OA and OTC (Le Bris and Pouliquen 2004). Exposure concentrations were intended to 
emulate unintended exposure by what might be encountered near aquaculture. Exposure concen-
trations were roughly 0.95 mg/L for OTC and 1.46 mg/L for OA. Uptake was determined for foot, 
muscle, mantle, viscera, gills. and shell. OTC concentrations were higher in viscera (1.83 mg/kg) 
than gills (0.37 mg/L), with other parts less than 0.2 mg/kg. OA concentrations were highest in gills 
(0.79 mg/kg) followed by shell (0.19 mg/kg). BAFs less than 1.0 were expected for these two highly 
ionized APls. 
Nie et al. (2008) found the bioaccumulation of ciprofloxacin by carp (Allogynogenetic crucian) 
under controlled feeding conditions to vary greatly, depending on several exposure scenarios. 
Feeding resulted in much higher residues (in visceral and muscle tissues) than via exposure to 
water. Uptake was fast, with maximum levels being reached within a day. The tissue concentrations 
(j1g/kg) resulting from each type of exposure were: water (muscle: 10; viscera: 42); feeding (muscle: 
73; viscera: 645); and dual exposure (muscle: 43; viscera: 368). 
8.2.6.9 Carbamazepine (CBZ) 
Juvenile rainbow trout were exposed under continuous flow for 96 h to 200 j1g/L CBZ (Huggett 
et al. 2004). After 24 h of exposure, the plasma concentrations of CBZ decreased, beginning at 
about 2.5 ng/mL and ending at less than 1 ng/mL, showing a low propensity to bioconcentrate. See 
the results for CBZ published by Ramirez (2007), Ramirez et al. (2007), and Zhou et al. (2008) sum-
marized under the section "Multianalyte Studies." In those studies, CBZ was also shown to poorly 
bioconcentrate, having a low BCF (<1). 
After a 60-day exposure to a high 19-ppm concentration of CBZ, no intracellular accumulation 
could be detected in the algae Ankistrodesmus braunii (Andreozzi et al. 2002). A method devel-
oped for determining CBZ in tissues was used to analyze a crustacean (Thamnocephalus platyurus) 
after it fed on algae (Pseudokirchneriella subcapitata) that had been previously exposed to CBZ 
at 250 mg/L (Lajeunesse et al. 2009). The mean CBZ concentration in dried T. platyurus was 129 
(±57) j1g/mg. 
8.2.6.10 Triclosan (and Methyl Triclosan) and Triclocarban 
With respect to the most heavily used biocides, triclosan [TCS: 5-chloro-2-(2,4-dichlorophen-
oxy)phenoll has been studied more frequently than triclocarban [TCe: N-(4-chlorophenyl)-N'-
(3,4-dichlorophenyl)urea]. In general, the transformation of triclosan to the more lipophilic methyl 
triclosan (MTCS: 4-chloro-I-(2,4-dichlorophenoxy)-2-methoxybenzene) leads to lower tissue levels 
of TCS compared with MTCS. Most of the research has been conducted in Europe and Scandinavia, 
with very recent studies in the United States (e.g., Leiker et al. 2009). Tissue residue levels of MTCS 
generally exceed those of any API-a result of higher BCFs and higher exposure levels. 
MTCS was first identified in fish by Miyazaki et al. (1984). Up to 38 ng/g was detected in the 
whole bodies of a freshwater fish (Carassius carassius) collected from Tama River, Tokyo Bay. 
Sams0e-Petersen et al. (2003) report on a monitoring study that sampled various aquatic species 
from 12 locations in Sweden, where concentrations ranged from less than 0.1 to 13 j1g/kg (wet 
weight). Much lower concentrations (in blood plasma) were reported in perhaps the first study from 
the United States, where Alaee et al. (2003) reported on fish from the Detroit River (Michigan-
Ontario) having TCS in the blood plasma of all 13 species surveyed; levels ranged from 0.61 ng/g 
wet weight (brown bullhead) to 10.4 ng/g (white bass). In contrast, MTCS was detected in the plasma 
of all 13 species but ranged only from 0.0004 ng/g for common carp to 0.0132 ng/g for largemouth 
bass; the presence of TCS at 3 orders of magnitude higher concentration than MTCS was ascribed 
to the higher lipophilicity of MTSC and its possible preferential partitioning to lipid tissue. 
Bile was analyzed for TCS in fish subjected to various exposure scenarios involving three 
WWTPs in Sweden, ranging from caged within effluent-dominated flows, to wild (or directly 
exposed to sewage under controlled compositions) (Adolfsson-Erici et al. 2002). Concentrations 
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ranged from 0.24 to 4.4 mg/kg bile (for wild fish) to 34-120 mg/kg (for those exposed directly to 
treated sewage effluent). 
Orvos et a1. (2002) assessed TCS bioconcentration in zebrafish (Dania reria) using continuous 
flow with 3 and 30 Ilg/L for 5 weeks followed by 2 weeks of depuration. During the 5-week expo-
sure, the BCFs ranged between 2000 and less than 3500 for the 39-llg/L exposure and from 3500 to 
about 5200 for the 3-llg/L exposure, giving average BCFs during the exposure period of 4157 at 3 
Ilg/L and 2532 at 30 Ilg/L. BCFs for head/scale and fillet ranged from about 1000 to 2000, whereas 
they ranged from about 8000 to 11,000 in the intestines for the low and high exposures, respectively. 
After depuration, the BCFs were 30 and 41 for the high and low exposures, respectively, so half-life 
residence time within the body was short compared with POPs. 
Boehmer et a1. (2004) performed a rare 10-year retrospective study (1994-2003) of breams 
(A. brama) from representative German rivers. The study revealed that TCS was rarely present 
in muscle while MTCS was detected in all specimens collected. In general, when present, TCS 
muscle-tissue concentrations remained relatively constant but low for any given river-less than 
1 ng/g wet weight. TCS concentrations were always lower than MTCS, which had excursions above 
30 ng/g wet-weight muscle. 
Balmer et a1. (2004) reported MTCS in fish (white fish, Careganus sp.; roach, R. rutilus) from 
various lakes in Switzerland receiving treated sewage effluents. Concentrations ranged up to 35 
ng/g (wet weight) or 365 ng/g (lipid basis) and fell within narrow ranges for a given lake. In another 
study of Swiss lakes, Balmer et a1. (2005) measured lipid levels of MTCS in fish lipids, where levels 
(ng/g) ranged from undetectable (perch) and 4-233 (roach), to 4-56 (whitefish). Buser et a!. (2006) 
examined the muscle tissue of brown trout (Salma truttafario), from seven Swiss rivers that receive 
treated sewage effluent, for MTCS. All concentrations were higher than those reported by Balmer 
et a!. (2005) for lake fish (white fish, Caregonus sp. and roach, R. rutilus). Concentrations ranged 
from 130 to 2100 ng/g, compared with the previous lake fish study of 4-370 ng/g. The concentra-
tions for river fish had considerable variation, possibly due to a more fluctuating input from sewage; 
river fish had higher concentrations probably because the exposure levels were higher. 
In a recent study, a survey of common carp from Las Vegas Bay revealed MTCS (but not TCS) in 
all 29 male common carp at a mean whole-body concentration of 600 Ilg/kg wet weight (7400 Ilg/kg 
on the basis of lipid, giving a BCF of 1.8 x 105) (Leiker et a1. 2009). Three chlorinated analogs (3- and 
5-chloromethoxy triclosan and 3,5-dichloromethoxy triclosan) were also present but less often and at 
lower concentrations, ranging from 0.5 to 13llg/kg in 21-76% of the samples; the brominated analog 
(bromomethoxy triclosan) was detected but not quantified. 
In contrast with MTCS, reported TCS levels are not as common and almost always lower (with 
the exception of blood plasma). The average TCS accumulation factor for zebrafish over a 5-week 
test period was 4157 at 3 mg/L and 2532 at 30 mg/L (Orvos et a1. 2002). TCS concentrations were 
highest in the digestive tract; head and muscle concentrations were similar. Following a 2-week 
depuration, the average BAF was 41 for 3 mg/L exposure and 32 for 30 mg/L exposure. The BCF 
was predicted to be roughly 2500. 
Houtman et a!. (2004) identified TCS at ppm levels in the nonpolar residual fraction of bile from 
wild fish in the Netherlands. Bile concentrations were about 14 Ilg/mL for fish from the North Sea 
Canal and 80 Ilg/mL for fish from the River Dommel. 
In a rare cross-species survey, TCS and MTCS were measured in the blood plasma of 13 species 
of fish (both benthic and pelagic) from a stretch of the "highly contaminated" Detroit River (Valters 
et a1. 2005). TCS levels ranged from 0.750 to 10.0 ng/g, while MTCS was present at 0.4-13.4 pg/L, 
3 orders of magnitude lower. TCS in the estuarine water samples averaged 7.5 ng/L, although the 
tissue and water sampling were temporally disconnected. Another feature of this study was the 
parallel analyses for a spectrum of brominated diphenyl ethers. 
Algae were shown to bioconcentrate TCS, MTCS, and TCC (Coogan et a!. 2007) by roughly 
3 orders of magnitude when collected from Pecan Creek, the same effluent-dominated stream in 
north Texas, U.S., previously studied by Brooks et a!. (2005) and Ramirez et a!. (2007). This may 
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be the first report of the bioconcentration of any of these three chemicals in algae; it may also be the 
first report of the bioconcentration of TCC by any organism. Dissolved concentration ranges (and 
algal wet-weight bioconcentration ranges and BAFs, Llkg) from four sampling sites for each of the 
three analytes were: TCS levels of <10-120 ng/L «10-146 Ilg/L; BAFs nil-2100); MTCS levels of 
<5-80 ng/L «5-89Ilg/L; BAFs nil-1500); and TCC levels of <15-190 ng/L (<10-401Ilg/L; BAFs 
nil-2700). 
Coogan and La Point (2008) extended these initial algal bioconcentration studies to examine 
snail (Helisoma trivolvis) bioaccumulation of TCS, MTCS, and TCC from the effluent outfall to 
Pecan Creek. Dissolved concentration ranges (and snail wet-weight bioconcentration level and 
BAFs) were: TCS level of 112 ng/L (58.7 Ilg/L; BAF 500); MTCS level of 41 ng/L (49.8 Ilg/L; 
1200); and TCC 191 ng/L (299 Ilg/L; 1600). Bioaccumulation of antimicrobials has been observed 
in other macroinvertebrates; adult grass shrimp accumulated MTCS after a 14-day exposure to 100 
Ilg/L TCS (Delorenzo et al. 2008). 
More recently, Mottaleb et al. (2009) reported mean (n = 11, ±SD) TCS levels at 21 ng/g (±4) in 
L. macrochirus (bluegill) from Pecan Creek, Texas. Although TCS was not detected in fish (Sonora 
sucker) collected from a relatively pristine location in the East Fork Gila River, New Mexico, TCS 
was detected at 12 ng/g in bluegill from Clear Creek, Texas, a regional reference site studied by 
Brooks et al. (2005) and Ramirez et at. (2007). This site does not receive point-source munici-
pal effluent, but may be influenced by onsite wastewater. In the Mottaleb et al. (2009) study, fish 
samples examined from Pecan Creek were the same organisms analyzed previously for target APIs 
by Ramirez et al. (2007). 
The most in-depth controlled study of TCC involved its uptake from sediments by the fresh-
water oligochaete L. variegatus (Higgins et al. 2009); depuration was also studied. TCC BSAFs 
were calculated and determined empirically during a 56-day study. Sediment spiked with TCC 
maintained a constant (and environmentally relevant) concentration over 56 days (22.4 ± 7.6 Ilg/g 
dry weight); the TCC concentration in the surrounding water also maintained constant, at 820 ± 220 
ng/L. Uptake by L. variegatus was rapid, reaching a maximum of 1310 ± 60 Ilg/g lipid or 42 ± 2llg/g 
wet weight at 5 days, after which levels began to decline. Bioaccumulation comported with predic-
tions from conventional models. Depuration was rapid. After 21 days in clean sediment, the TCC 
concentration in L. variegatus had declined to 9.6 ± 0.3 Ilg/g lipid (0.31 ± O.01llg/g wet weight). The 
BSAF ([mass of sediment organic carbon]/[mass of tissue lipid organic carbon]) after 56 days was 
calculated as l.6 ± 0.6. 
In a very rare study of higher-tropic-Ievel aquatic wildlife, triclosan was measured for the first 
time in a marine mammal-bottlenose dolphins (Tursiops truncatus) from two estuarine sites 
(Charleston, South Carolina, and Indian River Lagoon, Florida) (Fair et al. 2009). Both sites are 
influenced by discharged treated wastewaters. Blood-plasma levels ofTCS for one site ranged from 
0.12 to 0.27 ng/g (with 4 of the 13 having levels exceeding the MDL of 0.033 ng/g), and for the other 
site ranged from 0.085 to 0.106 (with 3 of 13 having detectable levels). These are possibly the highest 
plasma levels yet reported for any aquatic organism. TCS levels in the respective waters for the two 
sites averaged 7.5 ng/L, with a maximum of 13.7 ng/L. 
8.2.6.11 Miscellaneous APls 
In perhaps its first reported occurrence in fish from the wild, diazepam was quantified in liver 
samples from 10 hornyhead turbot (Pleuronichthys verticalis) collected near MWTP ocean dis-
charges in southern California (Kwon et al. 2009). The levels in five females ranged from 23 to 
45 ng/g (wet weight) and in five males from 58 to 110 ng/g (wet weight); EE2, CBZ, simvastatin, and 
oxybenzone were also targeted but not detected. 
Malachite green is a multiuse chemical. Although it has useful properties in aquaCUlture, its use 
in food is prohibited worldwide (see Sudova et al. 2007); nonetheless, it still experiences clandes-
tine use in aquaculture and can be used legally for ornamental fish. Because it is a chromophore, it 
also has a variety of other commercial uses unrelated to veterinary medicine-particularly as a dye. 
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Malachite green bioconcentrates readily in the lipid of aquatic organisms, primarily as its metabo-
lite leuco malachite green, which occurs at a ratio of 5-7:1. It persists in tissues, being found in the 
highest concentration in the liver. Schuetze et al. (2008) documented the occurrence of malachite 
green in the European eel (Anguilla anguilla L.) from lakes, rivers, and a canal in Berlin, Germany. 
Total concentrations of malachite green and the leuco form ranged up to 0.765 f./g/kg (wet weight) in 
25 of the 45 eels collected. Exposure was concluded to result from treated sewage. Although some 
of the bioconcentrated residue may have come from the use of malachite green for illegal and legal 
treatment of fish, an unknown but possibly large portion undoubtedly resulted from other commer-
cial uses, such as dyed textiles. 
8.2.6.12 API Disinfection By-Products CDBPs) and Metabolites 
Chlorination of either drinking water or wastewater containing steroids is known to produce mono-
and di-chlorinated products of varying estrogenic activity. Little has been published on DBPs from 
APIs. In the presence of bromide, which often occurs in surface waters and wastewaters, multiply-
brominated analogs can be formed (Lu and Korshin 2008). In particular, Lu and Korshin (2008) 
demonstrated the formation of stable dibromo-EE2. Buth et al. (2007) identified a number of prod-
ucts from the reaction of cimetidine with chlorine; Dodd and Huang (2004) identified products from 
sulfamethoxazole; and DellaGreca et al. (2009) identified various chlorinated and nonchlorinated 
products from atenolol. Similarly, Nakamura et al. (2007) identified a number of chlorinated estrones. 
The bioaccumulative potential for these reaction products is unknown. Similar issues surround the 
complex array of potential metabolites and other transformation products from parent APIs; many 
examples are reviewed by Farre et al. (2008) and by Kosjek and Heath (2008). Little work has been 
published on the possible metabolites from aquatic organisms. The recent work of Mehinto et al. 
(2010) revealed some possible metabolites from diclofenac in fish. 
Despite an increasing number of studies on API DBPs and other transformation products, there 
are very few studies regarding their uptake by aquatic organisms. In one of the only such studies, 
roach (R. rutilus) were exposed for 5 days in an aquarium filled with drinking water and spiked 
with EE2 at a nominal concentration of 30 ng/L; the measurable concentration in the test situation, 
however, was below the limit of detection (0.6 ng/L) (Flores and Hill 2008). EE2 was found to be 
rapidly brominated (yielding mono- and di-brominated EE2). Di-brominated EE2 (but no detect-
able mono-brominated EE2) accumulated in the ovaries and liver to levels 18- to 67-fold greater 
than the parent EE2. Concentrations (ng/g wet weight) ofEE2 and dibromo-EE2 detected were: liver 
(EE2: 2.7 and dibromo-EE2: 92.3) and ovaries (EE2: 0.2 and dibromo-EE2: 2.3), yielding a BCF for 
the ovaries of 130 and for the liver of 7894. 
8.2.7 UPTAKE BY AQUATIC PLANTS AND AERIAL INVERTEBRATES 
The uptake of APIs by plants and algae, which compose an important part of the aquatic food chain, 
might prove a significant part of dietary exposure. Indeed, uptake of APIs by certain plants is so 
efficient that they have been evaluated for in-situ phytoremediation of contaminated waters and 
sediments (e.g., Forni et al. 2002). Plant uptake has been particularly germane to aquaculture sites. 
A discrete body of work has been published on the uptake of APls by aquatic plants. The aquatic 
bryophyte Fantinalis antipyretica is known to bioconcentrate metals, pesticides, and PAHs and 
has therefore been used in situ as a bioindicator for integrative monitoring. A study of the uptake 
of three antibiotics widely used in aquaculture (OA, flumequine, and OTC) showed BCFs rang-
ing from 75 (flumequine) to 450 (OTC) (Delepee et al. 2004). These antibiotics had mean tissue 
residence times of 18 and 59 days. The study was conducted at relatively high concentrations of 
100 and 1000 ppb. BCFs were higher at the lower concentrations and were an inverse function of 
K"w-increasing according to ionization instead of lipophilicity. 
In a study of transpiration stream concentration factors (TSCFs) versus polarity, Dettenmaier 
et al. (2009) showed that polar but nonionizable, highly water soluble organic compounds can be 
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easily taken up by plant roots and translocated to shoot tissue. Studies on uptake of APls by plants 
(primarily bryophyte) have generally revealed rather high levels, and sometimes the source was 
not necessarily related to aquaculture, as upstream samples have at times shown similar levels. 
Pouliquen et al. (2009) examined bryophytes as biomonitors downstream of aquaculture and sew-
age. They reported maximum tissue concentrations (ng/g) for OA (47), flumequine (-600), OTC 
(1200), and florfenicol (513). 
Migliore et al. (2000) exposed an aquatic weed (Lythrum salicaria L.) to flumequine. After 
35 days, the dry-weight tissue concentrations were in the ppm range: 13.3, 8.7, 0.7, 0.3, and 0.2 Ilg/g at 
flumequine aqueous concentrations of 5000, 1000,500, 100, and 50 Ilg/L, respectively. Exposure 
of an aquatic fern (Azolla filiculoides Lam.) to sulfadimethoxine for 5 weeks at concentrations 
of 50, 150,300, and 450 mg/L resulted in uptake at the mg/g dry-weight level (1000 ppm) (Forni 
et al. 2002). Typha was shown to rapidly absorb clofibric acid at 20 Ilg/L, removing more than 
50% within 48 h (Dordio et al. 2008). 
Redshaw et al. (2008) recently used a Brassicaceae (cauliflower) model to examine fluoxetine 
uptake by plants. Following a 12-week exposure to 280 Ilg/L fluoxetine in growth media, fluoxetine 
concentrations were higher in the stems (0.49 Ilg/g wet weight) than in leaf tissues (0.26 Ilg/g wet 
weight) of Brassicaceae. This study did not examine steady-state tissue levels of fluoxetine; this is 
important because fluoxetine is photolabile and should have degraded over the 12-week study period 
(Redshaw et al. 2008). However, presence of low Ilg/g-levels of fluoxetine suggest bioconcentra-
tion, which did not correlate with lipid content in leaf and stem tissues of Brassicaceae. Although 
cauliflowers are terrestrial plants and this study was specifically interested in estimating potential 
fluoxetine uptake in terrestrial plants exposed to biosolid-amended soils, it suggests that fluoxetine 
accumulation by nonrooted aquatic macrophytes such as Lemna sp. should be considered (Redshaw 
et al. 2008). 
Coexposure to APls will often occur with varying nutrient ratios and stoichiometries. Nutrient 
enrichment was previously demonstrated to influence the magnitude of triclosan toxicity to 
L. gibba, for both traditional morphometric endpoints (Fulton et al. 2009) and nontraditional 
responses, such as internal C:N:P and nitrate uptake kinetics (Fulton et al. 2010). Because nutrient 
stoichiometry can also influence internal lipid metabolism and concentrations in plants and algae, 
site-specific nutrient enrichment differences may result in differential bioconcentration of APls 
(Fulton et al. 2010). 
The potential for trophic transfer of APls out of the aquatic realm was recently shown by Park 
et al. (2009). EE2 was determined in aerial invertebrates (primarily Diptera) whose larval stages 
develop in STP percolating filter beds. EE2 concentrations in insects captured near STPs were sig-
nificantly higher than in those over 2 km away. The median EE2 tissue concentration was 42 ng/g 
(with the 75th percentile 140 ng/g) from insects near the STPs, compared with a median level of less 
than 3 ng/g (and 9 ng/g 75th percentile level) detected in the insects more distant from the STPs. 
Further transfer to insectivorous bats and birds was postulated. Rough calculations estimated that 
daily exposure to EE2 for bats feeding on insects near the STPs could range from 9 to 159 ng/g. 
8.2.8 MULTIANALYTE STUDIES 
Studies that target multiple APls to gauge ambient exposure are indeed rare. The recent study of 
Schultz et al. (2010) targeting 10 antidepressants (including two metabolic/transformation products) 
was discussed earlier. The first and most comprehensive multianalyte study to date on fish tissue was 
by Ramirez et al. (2007). From a target list of 23 APls and 2 metabolites, only four were reported as 
being detected. Fish (Lepomis sp.) were sampled in Texas from an effluent-dominated stream (n = 11) 
and from another creek (n = 20) that served as reference. The four APls were detected in muscle 
from all samples in the study site. The range (and mean; ng/g wet weight) were: diphenhydramine 
[0.66-1.32 (0.96)]; diltiazem [0.11-0.27 (0.21)]; CBZ [0.83-1.44 (1.16)]; and norfluoxetine [3.49-5.14 
(4.37)]. This is the first report of diphenhydramine, diltiazem, and CBZ in wild fish. 
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With impetus provided by the Brooks et al. (2005) study, the U.S. EPA initiated the National 
Pilot Project of pharmaceuticals and PCPs (PPCPs) in Fish Tissue (U.S. EPA 2008a), which repre-
sents the first national-scale reconnaissance study of PPCPs in fish tissue (Ramirez 2007, Ramirez 
et al. 2009). Sample collection and processing procedures followed approaches previously used 
during the U.S. EPA's National Study of Chemical Residues in Lake Fish Tissue. Analytical meth-
ods for PPCPs in the National Pilot Project employed approaches previously developed by Ramirez 
et al. (2007) and Mottaleb et al. (2009). Because effluent-dominated and effluent-dependent ecosys-
tems represent worst-case scenarios for API exposure (Brooks et al. 2006), five effluent-dominated 
river systems were selected for study: Phoenix, AZ; Orlando, FL; Chicago, IL; West Chester, PA; 
and Dallas, TX. The Gila River, NM was selected as a reference site for this study. Ramirez et al. 
(2009) targeted 25 APTs/metabolites in the fillets and livers from wild-caught fish: acetaminophen, 
atenolol, caffeine, CBZ*, cimetidine, clofibric acid, codeine, diltiazem*, 1,7-dimethylxanthine, 
diphenhydramine*, erythromycin, fluoxetine*, gemfibrozil*, ibuprofen, lincomycin, metoprolol, 
miconazole, norfluoxetine*, propranolol, sertraline*, sulfamethoxazole, thiabendazole, trimetho-
prim, tylosin, warfarin. The four shown in italics had MDLs below I ng/g. The seven with asterisks 
were detected in multiple fish from multiple locations. Of these seven that were detected, three had 
the lowest MDLs (CBZ, diltiazem, and diphenhydramine) in both fillet (less than I ng/g) and liver 
(less than 2 ng/g), while only two (fluoxetine and gemfibrozil) were among those with the highest 
MDLs (greater than 6 ng/g in fillet and 12 ng/g in liver). Of the seven APIs with the highest MDLs, 
only one (gemfibrozil) was detected. 
At only one of the five sites, receiving effluent from a sewage treatment facility using tertiary 
treatment, none of the target APIs was detected in the fillet from any fish; also no API was detected 
in any fish from a nonimpacted reference site. All of the seven APIs detected among the 25 targeted 
APIs were detected in fish from only one site, which received effluent from secondary treatment. 
Mean concentrations in fillet for all the detected APIs were generally less than 3 ng/g and ranged 
from 0.04 to 11 ng/g. The majority of the mean concentrations in liver for all the detected APIs 
were generally greater than 6 ng/g and ranged from 0.03 to a high of 380 ng/g (sertraline). Except 
for one site where fluoxetine was found in fillet but not in liver (and where the liver also contained 
substantially more norfluoxetine), the APT concentrations in livers were always larger-by several 
fold or by over one order of magnitude. Of significance, API concentrations did not correlate with 
lipid content-a finding shared with other published studies. 
Another study targeted five APIs during the course of ground truthing a new in vivo tissue sam-
pling method using implanted solid-phase micro extraction (SPME) fibers (Zhou et al. 2008). The tar-
geted APIs were the ones previously reported by Ramirez et al. (2007): diltiazem, diphenhydramine, 
CBZ, and norfluoxetine. Under controlled exposure conditions, rainbow trout (0. mykiss) gave BCFs 
for CBZ in muscle after 7- and 14-day exposures of 0.44 and 0.22, respectively. Significantly, free and 
total tissue levels after 14 days were lower than those after 7 days. The authors postulated that CBZ 
metabolism was upregulated during the exposure time. The bioconcentration of fluoxetine differed 
markedly. While the respective free concentrations in muscle after 7 and 14 days of exposure were 
only 0.30 and 0.65 times those in the aqueous media, the BCFs for total fluoxetine in muscle were 62 
and 84, respectively. The same approach was used for determining muscle levels of free API in wild 
fish captured from streams that received treated sewage. These are the only reports of "free" APIs in 
aquatic tissues. In the wild fish, only diltiazem and diphenhydramine were detected. Free diltiazem 
muscle concentrations were 2.04 and 5.69 pg/g in the white sucker (c. commersoni) and Johnny darter 
(Etheostoma nigrum), respectively. Free diphenhydramine concentrations were 32.0 and 81.6 pg/g for 
white sucker and Johnny darter, respectively. These concentrations are several orders of magnitude 
lower than the conventional "total" levels reported by all previous investigations. 
A more recent study (Fick et al. 2010), which was built on previous efforts by Brown et al. 
(2007), exposed rainbow trout to final treated effluent for 14 d at three different sites in Sweden 
(Umea, Stockholm, and Gothenburg). Of the 25 API analytes targeted, 16 were detected in fish 
plasma (sampled from at least one study location) at levels exceeding one-thousandth of their 
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respective human plasma levels associated with therapeutic dose (CmaJ. One of these 16 APTs of 
particular significance was the synthetic progestin levonorgestrel-at plasma levels of 8.5 and 12 ngl 
mL, a level4-fold greater than human plasma Cmax . This plasma level of levonorgestrel represented 
an empirical BCF of 12,000, which was 200-fold higher than the predicted BCF. Such approaches 
for relating internal-dose API exposures to potential effect thresholds are explored further below. 
Finally, the study of Kwon et al. (2009), as discussed earlier, targeted five APIs: EE2, diazepam, 
CBZ, simvastatin, and oxybenzone. Only the first two, however, were detected in liver samples from 
hornyhead turbot (P. verticalis) from southern California. 
8.2.9 SUMMARY OF PUBLISHED DATA 
Much of the data for APIs/metabolites and related DBPs in this chapter on aquatic tissue-levels and 
BCFs/BAFs compiled from the published literature is summarized in Table 8.4. Included in the 
table is an indication of historical precedence-whether the data were the first to be reported; most 
of the data are "firsts," revealing that the depth of the published data in terms of repeated measure-
ments is very shallow. 
TABLE 8.4 
Summary of Bioconcentration Data for APls in Aquatic Tissues 
APls Studied in 
Wild Specimens 
(Controlled In Situ 
Studies Indicated 
by Asterisk*) 
Bupropion 
Citalopram 
Pluoxetine 
Maximum 
Concentration in 
Wild Specimens 
(Ilglkg) (Controlled 
Studies Indicated 
by Asterisk*) 
0.013-0.07 brain 
0.57 plasma 
0.01-0.07 brain 
1.58 brain 
1.34 liver 
0.02-0.6 brain 
Historical 
Precedence in 
Literature Notes Reference 
Antidepressants 
Probably I st Detected in samples from 5 of 8 Schultz et a1. 
report 
Possibly 1st 
report 
Probably 1st 
report 
Probably J st 
reports 
streams; upper range = 0.348 
ng/g. Water = 20-50 nglL. 
Sharks. 
(2010) 
Gelsleichter 
(2009) 
Detected in samples from 4 of 8 Schultz et a1. 
streams; upper range = 0.212 (2010) 
ng/g. Water = 4.5-70 ng/L. 
Lowest concentrations in 
muscle. Empirical BCFs up to 
260 for body and 3100 for 
liver (Nakamura et a1. 2(08); 
but BCF for "free" ftuoxetine 
less than unity (Zhou et a1. 
2008). Controlled exposure to 
0.55 gIL gave peak 
concentration of 49 flg/kg 
tissue (Paterson and Metcalfe 
2008). 
Brooks et a1. 
(2005) [also 
Chu and 
Metcalfe (2007)] 
Detected in samples from 6 of 8 Schultz et a1. 
streams; upper range = 1.6 
ng/g. Water = 1-9 ng/L. 
(2010) 
continued 
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TABLE 8.4 (continued) 
Summary of Bioconcentration Data for APls in Aquatic Tissues 
Maximum 
APls Studied in Concentration in 
Wild Specimens Wild Specimens 
(Controlled In Situ (J.Ig/kg) (Controlled Historical 
Studies Indicated Studies Indicated Precedence in 
by Asterisk*) by Asterisk*) Literature Notes Reference 
Norfluoxetine 10.27 liver Probably 1st Lowest concentrations in muscle. Brooks et al. 
8.86 brain reports Controlled exposure to 0.55 (2005) [also 
nglL of fluoxetine gave peak Chu and 
concentration of 64 /lg/kg tissue Metcalfe (2007)] 
(Paterson and Metcalfe 2008). 
0.07-0.9 brain Detected in samples from 5 of 8 Schultz et al. 
streams; upper range = 3.6 (2010) 
ng/g. Water = 0.9-4 nglL. 
Paroxetine 0.58 whole body Probably 1st Chu and Metcalfe 
report (2007) 
0.005-1.8 brain Detected in samples from 6 of 8 Schultz et al. 
streams; upper range = 4.2 (2010) 
ng/g. Water = 2-4 nglL. 
Sertraline 4.27 brain Probably 1st Lowest concentrations in Brooks et al. 
3.59 liver reports muscle. (2005) 
1.1-1.2 plasma Fish exposed to treated sewage Fick et al. (2010) 
effluent; 2 of 3 sites in 
Sweden; BCF > 138-240 
(predicted = 959). 
N orsertraline 15.6 brain Probably 1 st Lowest concentrations in Brooks et al. 
12.94 liver reports muscle. (2005) 
0.01-3 brain Detected in samples from 7 of 8 Schultz et al. 
streams; upper range = 28.9 (2010) 
ng/g. Water = 1.1-6 nglL. 
0.01-0.02 brain Detected in samples from 3 of 8 Schultz et al. 
streams; upper range = 0.113 (2010) 
ng/g. Water = 0.8-4 nglL. 
Venlafaxine 0.32 plasma Possibly 1st Sharks. Gelsleichter 
report (2009) 
0.02-0.1 brain Detected in samples from 2 of 8 Schultz et al. 
streams; upper range = 1.12 (2010) 
ng/g. Water = 102-220 nglL. 
NSAIDs 
Diclofenac 12 plasma Probably 1st BCF = 5. First report of Brown et al. 
report bioconcentration (under (2007) 
controlled conditions) gave mgl 
kg concentrations in liver and 
kidney, with BCFs of nearly 
3000 [Schwaiger et al. (2004) J. 
2.2-20 plasma Fish exposed to treated sewage Fick et al. (2010) 
effluent; 3 of 3 sites in Sweden; 
BCF = 2.5-29 (predicted = 93). 
328 bile Probably 1 st 21-day exposure of trout to Mehinto et al. 
report in bile 0.5 ng/mL; BCF = 657. (2010) 
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TABLE 8.4 (continued) 
Summary of Bioconcentration Data for APls in Aquatic Tissues 
Maximum 
APls Studied in Concentration in 
Wild Specimens Wild Specimens 
(Controlled In Situ (Ilglkg) (Controlled Historical 
Studies Indicated Studies Indicated Precedence in 
by Asterisk*) by Asterisk*) Literature Notes Reference 
Ibuprofen 84 plasma Possibly 1st BCF= 18,667. Brown et al. 
report (2007) 
S.S-102 plasma Fish exposed to treated sewage Fick et al. (2010) 
effluent; 3 of 3 sites in 
Sweden; BCF = 21-S8 
(predicted = 77). 
Ketoprofen Undetected Probably 1st Did not bioconcentrate. Brown et al. 
attempted (2007) 
analysis 
IS-I07 plasma Probably 1st Fish exposed to treated sewage Fick et al. (20 I 0) 
report effluent; 3 of 3 sites in 
Sweden; BCF = 3.S-48 
(predicted = 20). 
Naproxen 14 plasma Probably 1st BCF = S6. Brown et al. 
report (2007) 
33-46 plasma Fish exposed to treated sewage Fick et al. (2010) 
effluent; 3 of 3 sites in 
Sweden; BCF = 22-28 
(predicted = 24). 
Lipid Regulators Calculated BCFs for a number of fibrates and statins are provided by Hernando et al. (2007); 
values ranged 120--380 for clofibrate, fenofibrate, lovastatin, and mevastatin, but higher for 
simvastatin (800) and ftuvastatin (2000). 
Gemfibrozil 210 plasma Probably 1st BCF = 199. Plasma Brown et al. 
report concentration of 170 Ilg/L (2007) 
yielded a BCF of SOO after 
controlled exposure to 0.34 
IlglL (Mimeault et al. 200S). 
f1-Blockers Not detected in studies of 
Brooks et al. (200S) and 
Brooks (unpublished data). 
Atenolol* SI plasma* Probably 1st Controlled exposure to Winteret al. 
report (for 3.2 mglL. Calculated BCF (2008) 
controlled diminishingly low (Cleuvers 
exposure) 200S). 
Propranolol * S plasma* Probably 1st Controlled exposure to 10 mglL Owen et aI. 
report (for for 10 days. (2007; also 
controlled unpublished 
exposure) data) 
Fungicides 
Nine triazoles* SOO-IOOO body Probably 1st Exposed via feed at Konwick et al. 
lipid* report (for concentrations of (2006) 
controlled 23-3S mg/kg w/w. 
exposure) 
continued 
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TABLE 8.4 (continued) 
Summary of Bioconcentration Data for APls in Aquatic Tissues 
Maximum 
APls Studied in Concentration in 
Wild Specimens Wild Specimens 
(Controlled In Situ (lig/kg) (Controlled Historical 
Studies Indicated Studies Indicated Precedence in 
by Asterisk*) by Asterisk*) Literature Notes Reference 
Macrocyclic Residues well-established as See overview: 
Lactones occurring in liver and lipids. Danaher et al. 
(avermectins) (2006). 
Abamectin* 38.29 muscle* Controlled 22-d exposure to Shen et al. (2005) 
I /lg/L; BCF = 42. 
Avennectin Bla* 6.8. 3.0, and II * in One of earliest Controlled 28-d exposure to Van den Heuvel 
whole fish, fillet, reports for I /lglL; BCFs of 56, 28, and 84. et al. (1996) 
and viscera controlled 
exposure 
Steroids Considerable data exist on See overview: 
uptake of endogenous Tyler et al. 
estrogens under controlled in (2008). 
situ conditions (not 
summarized here). 
EE2 1100 bile Perhaps 1st 4-week exposure in effluent- Larsson et al. 
bioconcentration dom inated stream; controlled (1999) 
study 46-h exposure to 5 /lglL gave 
350,000 /lglL in bile; 
bioconcentration is in the 
range of 4-6 orders of 
magnitude. 
3.79 plasma Juvenile sharks in wild. Gelsleichter 
(2009) 
EE2* 31 tissue* Perhaps the first Lifecycle/posthatch exposure to Lange et al. 
full life-cycle 64 nglL. BCFs probably less (2001) 
bioconcentration than 500-2400. No detectable 
study ofEE2 residues after exposure to 
I nglL. 
32--40 (E2eq) bile* Also detected in testes and Gibson et al. 
ovaries. (2005a) 
EE2 dibrominated* 92.3 liver* Perhaps I st study Roach exposed for 5 days to Flores and Hill 
2.3 ovaries * (controlled) drinking water with (2008) 
targeted at API measurable EE2 of 0.6 nglL. 
DBPs Accumulated concentrations 
18-67 greater than those 
measured for EE2. BCFs 7894 
(liver) and 130 (ovaries). 
Levonorgestrel 8.5-12 plasma Probably 1st Fish ex posed to treated sewage Fick et al. (2010) 
report effluent; 2 of 3 sites in 
Sweden; BCF = 12,000 
(predicted = 46). 
Testosterone* 80 plasma* 6-day exposure to I /lglL; Maunder et al. 
plasma levels dropped quickly (2007) 
upon cessation of exposure. 
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TABLE 8.4 (continued) 
Summary of Bioconcentration Data for APls in Aquatic Tissues 
APls Studied in 
Wild Specimens 
(Controlled In Situ 
Studies Indicated 
by Asterisk*) 
Equilenin* 
17~ 
Dihydroequilenin* 
Maximum 
Concentration in 
Wild Specimens 
(Ilg/kg) (Controlled 
Studies Indicated 
by Asterisk*) 
3Q....40 (E2eq) bile* 
Historical 
Precedence in 
Literature 
Probably 1st 
report (for 
exposure to 
treated sewage) 
Probably 1st 
report (for 
exposure to 
treated sewage) 
Notes 
BCF = 2.2 x 106 
BCF = 1.5 x 106 
321 
Reference 
Tyler et al. (2009) 
Gibson et al. 
(2005a,2005b) 
Antibiotics Considerable data exist for tissue levels resulting from the high exposures used in aquaculture. 
Miscellaneous 
Carbamazepine 
(CBZ) 
Cilazapril 
Diazepam 
Diltiazem 
Some data exists from controlled studies that simulate the indirect exposure that might occur for 
organisms in the vicinity of an aquaculture operation. See text for discussion. 
2.5 plasma* 
0.3~ 1.0 plasma 
0.83~ 1.44 muscle 
129,000* crustacean 
None detected in 
algae 
0.1~0.7 plasma 
23~110 liver 
0.11-0.27 muscle 
0.002~0.0056 
muscle 
0.9 plasma 
Perhaps 1st 
report (for 
controlled 
exposure) 
I st report in wild 
fish 
Trophic-level 
transfer 
Possibly 1st 
report 
Possibly 1st 
report 
1 st report in wild 
fish 
I st report of 
"free" 
concentrations 
in wild 
24-h exposure to 200 flglL; 
BCF < I. 
Fish exposed to treated sewage 
effluent; 3 of 3 sites in 
Sweden; BCF = 0.8-4.2 
(predicted = 6). 
II specimens from effluent-
dominated stream. 
Concentration on basis of dried 
weight; fed algae that had been 
exposed to CBZ. 
Exposed to 19 ppm. 
Fish exposed to treated sewage 
effluent; 2 of 3 sites in 
Sweden; BCF> 100-700 
(predicted = 6). 
CBZ and simvastatin also 
targeted but not detected. 
II specimens from effluent-
dominated stream. 
Fish exposed to treated sewage 
effluent; I of 3 sites in 
Sweden; BCF = 24~ 139 
(predicted = 14). 
Huggett et al. 
(2004) 
Fick et al. (201 0) 
Ramirez et al. 
(2007) 
Lajeunesse et al. 
(2009) 
Andreozzi et al. 
(2002) 
Fick et al. (2010) 
Kwon et al. 
(2009) 
Ramirez et al. 
(2007) 
Zhou et al. (2008) 
Fick et al. (201 0) 
continued 
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TABLE 8.4 (continued) 
Summary of Bioconcentration Data for APls in Aquatic Tissues 
Maximum 
APls Studied in Concentration in 
Wild Specimens Wild Specimens 
(Controlled In Situ (Ilglkg) (Controlled Historical 
Studies Indicated Studies Indicated Precedence in 
by Asterisk') by Asterisk') Literature Notes Reference 
Diphenhydramine 0.66-1.32 muscle 1 st report in wild II specimens from effluent- Ramirez et al. 
fish dominated stream. (2007) 
0.032-0.082 muscle I st report of Zhou et al. (2008) 
"free" 
concentrations 
in wild 
Haloperidol 1.2 plasma Possibly 1st Fish exposed to treated sewage Fick et al. (2010) 
report effluent; 1 of 3 sites in 
Sweden; BCF = 3.2 (predicted 
= 153). 
Meclozine 0.1-0.7 plasma Possibly 1st Fish exposed to treated sewage Fick et al. (20 I 0) 
(meclizine) report effluent; 2 of 3 sites in 
Sweden; BCF > 200-1400 
(predicted = 2521). 
Memantine 2.3 plasma Probably 1st Fish exposed to treated sewage Fick et al. (2010) 
report effluent; I of 3 sites in 
Sweden; BCF < 50-164 
(predicted = 36). 
Orphenadrine 0.9 plasma Probably 1st Fish exposed to treated sewage Fick et al. (2010) 
report effluent; I of 3 sites in 
Sweden; BCF < 63-100 
(predicted = 61). 
Oxazepam 0.2-0.7 plasma Probably 1st Fish exposed to treated sewage Fick et al. (2010) 
report effluent; 3 of 3 sites in 
Sweden; BCF = 0.7-3.6 
(predicted = 7). 
Risperidone 0.3-2.4 plasma Probably 1st Fish exposed to treated sewage Fick et al. (2010) 
report effluent; 3 of 3 sites in 
Sweden; BCF > 60-480 
(predicted =47). 
Tramadol 1.1-1.9 plasma Probably 1st Fish exposed to treated sewage Fick et al. (2010) 
report effluent; 3 of 3 sites in 
Sweden; BCF = 2.3-3.3 
(predicted = 20). 
Verapamil 0.7 plasma Probably 1 st Fish exposed to treated sewage Fick et al. (2010) 
report effluent; I of 3 sites in 
Sweden; BCF < 33-175 
(predicted = 40). 
Triciosan, TCS: 5-chloro-2-(2,4-dichlorophenoxy)phenol 
Methyl triciosan, MTCS: 4-chloro-I-(2,4-dichlorophenoxy)-2-methoxybenzene 
Triciocarban TCe: N -( 4-chlorophenyl)-N' -(3 ,4-dichlorophen yl )urea 
TCS 0.61-10.4 plasma 1st report in U.S. Detected in all 13 species Alaee et al. 
surveyed. (2003) 
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TABLE 8.4 (continued) 
Summary of Bioconcentration Data for APls in Aquatic Tissues 
Maximum 
APls Studied in Concentration in 
Wild Specimens Wild Specimens 
(Controlled In Situ (fig/kg) (Controlled Historical 
Studies Indicated Studies Indicated Precedence in 
by Asterisk') by Asterisk') literature Notes Reference 
0.75-10.0 plasma 13 species from Detroit River. Valters et al. 
MCTS levels 0.0004-0.013 (2005) 
Ilgikg, 3 orders of magnitude 
lower. 
85-270 plasma 1st report in Detected in 7 of 26 dolphins. Fair et al. (2009) 
marine Possibly highest plasma level 
mammal reported for any aquatic 
organism. 
240 to 4400 bile Possibly 1st Adolfsson-Erici 
report (in bile et al. (2002) 
of wild fish) 
14,000-80,000 bile The Netherlands Houtman et al. 
(2004) 
35 whole body; 365 Swiss lakes Balmer et al. 
lipid (2004) 
21 whole body Mottaleb et al. 
(2009) 
146 algae whole 1 st report in Algal BAF: <2100 Coogan et al. 
body snail Snail BAF: 500 (2007) 
58.7 snail whole Coogan and La 
body Point (2008) 
TCS-halogenated 0.5-13 whole body I st report of 3- and 5-chloromethoxy TCS; Leiker et al. 
analogs halogenated 3,5-dichloromethoxy TCS; (2009) 
products unidentified bromomethoxy 
TCS; detected in 21-76% of 
29 carp from Las Vegas Bay. 
MTCS 38 whole bodies 1st report Miyazaki et al. 
(1984) 
0.1-13 whole Monitoring study of multiple Sams0e-Petersen 
bodies species at 12 locations in et al. (2003) 
Sweden. 
600 whole body; Detected in all 29 carp from Las Leiker et al. 
7000 lipid Vegas Bay. TCS not detected. (2009) 
BCF = 1.8 x 105 
0.0004-0.0132 1st report in U.S. Detected in all 13 species Alaee et al. 
plasma surveyed. (2003) 
30 muscle I O-year retrospective study of Boehmer et al. 
breams. MTCS was always (2004) 
detected, but TCS was rarely 
present. 
130-2100 muscle Seven Swiss rivers Buser et al. 
(2006) 
continued 
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TABLE 8.4 (continued) 
Summary of Bioconcentration Data for APls in Aquatic Tissues 
Maximum 
APls Studied in Concentration in 
Wild Specimens Wild Specimens 
{Controlled In Situ (JIg/kg) (Controlled Historical 
Studies Indicated Studies Indicated Precedence in 
by Asterisk*) by Asterisk*) literature Notes Reference 
4-233 lipid Swiss lakes Balmer et al. 
(2005) 
89 algae whole body 1st report in Algal BAF: <1500 Coogan et al. 
49.8 snail whole snail Snail BAF: 1200 (2007) 
body Coogan and La 
Point (2008) 
TCC 401 algae whole I st report in any Algal BAF: <2700 Coogan et al. 
body organism Snail BAF: 1600 (2007) 
299 snail whole I sl report of Worm BSAF: ca 2 Coogan and La 
body BSAF Point (2008) 
42,000 worm whole Higgins el al. 
body* (2009) 
Considering the data for all APIs (excluding triclosan and its derivatives) on aquatic tissue 
levels or bioconcentration, the following can be noted. Only a handful of studies predate 2003. The 
concentrations for the majority of APIs range from I to 100 /-lg/kg regardless of tissue type. Those 
APls showing higher concentrations include gemfibrozil and triazole fungicides. Most data are for 
controlled in situ exposures rather than for organisms sampled in the wild. Data for tissue levels 
in wild samples exist for roughly 21 APIs and metabolites. Data for controlled studies exist for 
about 9 APIs; the study of Fick et al. (2010) exposed fish to treated sewage effluent and quantified 
an additional 10 unique APls. Data for tissue levels exist for roughly 40 human APIs/metabolites 
(excluding antibiotics) but many are from single studies. Steroids are commonly quantified as 
total (conjugates combined with free). Of the existing calculated empirical BCFs, except those for 
steroids, nearly all are lower than several thousand, most being lower than 100. More data exist 
for estrogens (especially endogenous estrogens) and triclosan (including MTCS and other deriva-
tives) than for any other class of APIs; surprisingly, despite its high usage (similar to triclosan), 
very little data exists for triclocarban. MTCS, unlike TCS, does not concentrate in plasma. Tissue 
concentrations for both TCS and MTCS can exceed tens of thousands /-lg/kg, with BCFs up to the 
range of several million. 
8.3 FACTORS INFLUENCING EXPOSURE 
8.3.1 GENERAL CONSIDERATIONS 
It is important to keep in mind the difficulty in comparing BCFs between APIs (or even for a given 
API) or between species of fish and other aquatic organisms. The wide range of variables in Table 
8.3 can add tremendous variability to these values. But moreover, BCFs are reported on different 
bases, not just whole body; these include different tissues or on a wet-weight basis or on the basis 
of lipid content. They can also use empirical data generated by static (steady-state equilibration and 
non steady-state) or kinetic uptake measurements, as well as nominal exposure levels that span one 
or more orders of magnitude (sometimes exceeding the solubility, and other times the uptake rate is 
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the limiting factor, resulting in lower BCFs at higher exposures). These factors make it difficult to 
distill existing data into succinct generalizations. 
Various models have been developed in attempting to link aquatic tissue residues with biological 
effects. As an example, attempting to establish a more realistic measurable linkage of exposure with 
effects, the CBR concept holds that the whole-body concentrations across species does not vary 
wildly among chemical stressors sharing the same MOA for a given biological endpoint. The CBR 
is supposedly relatively consistent for a given endpoint, whether acute or chronic. Its appeal derives 
from the assumption that levels of chemical stressors internal to an organism more directly dictate 
receptor interaction than doses calculated from surrounding ambient concentrations. By the nature 
of its definition, CBR should be relatively independent of the stressor's ambient concentration in the 
immediate aqueous environment. The CBR concept supposedly accounts for a measure that is more 
closely associated with the level of stressor that would actually interact with the receptor. However, 
in a critical examination of CBR by Barron et al. (2002), published data were not found to support 
the CBR concept among members from groups of chemicals sharing the same MOA; variability in 
correlation with effects was found to be as great as other measures such as ambient concentration. 
Many variables may be at work here. For example, it is not known whether bioaccumulated residues 
are readily bioavailable, or if rather, only the free residues are (e.g., Zhou et al. 2008). 
These issues, together with the many terms used in aquatic exposure (e.g., bioconcentration, bio-
accumulation, biomagnification, bioavailability, and biomarkers) and exposure's role in assessing 
aquatic health, are discussed in the comprehensive work of Geyer et al. (2000), Gobas and Morrison 
(2000), and van der Oost et al. (2003). What measure of stressor level experienced by an organism 
serves as the best surrogate for true dose remains elusive. Below we examine several important 
variables that may be critical for ecological risk assessments of APIs. 
8.3.2 SELECT SITE-SPECIFIC FACTORS INFLUENCING EXPOSURE 
8.3.2.1 Hydrology 
Effluent-dominated ecosystems may be defined as receiving systems in which more than 50% of 
the in-stream flow results from effluent discharges. Effluent-dependent conditions result seasonally 
when the in-stream flow of these receiving systems is entirely dependent on effluent discharges. In 
more arid or semiarid regions experiencing rapid urbanization, effluent-dominated or dependent 
conditions are common (Brooks et al. 2006). Examples of effluent-dominated large river systems 
include the Trinity River in Texas and the South Platt River in Colorado (Brooks et al. 2006). 
Prospective environmental assessments of APIs often include a default in-stream dilution factor 
of 10 when predicting expected environmental concentrations (Brooks et al. 2003), which are not 
representative or protective of effluent-dominated or dependent ecosystems. 
In an attempt to estimate effluent-dominated conditions in the United States, Brooks et al. (2006) 
examined information from the U.S. EPA on receiving system critical dilution limits included in 
the National Pollutant Discharge Elimination System (NPDES) program (U.S. EPA 1991). Under 
annual mean flow, it was estimated that less than 20% of discharges entered receiving systems with 
less than 1O-fold dilution, but this value increased three fold to approximately 60% of in-stream 
dilution occurring at less than 10 fold during low flow conditions (e.g., 7Q1O, the seven consecutive-
day lowest flow with a 1O-year recurrence interval) (Brooks et al. 2006). 
The NPDES data summarized above was quite dated. New discharges or increased treatment 
demands on existing dischargers frequently result from increasing population growth. Thus, Brooks 
et al. (2006) examined a representative sample of NPDES permits (582) in U.S. EPA Region 6, 
which comprises the states of Arkansas, Louisiana, Oklahoma, New Mexico, Texas, and a number 
of Tribes. The minimum (or critical) dilution limit for a wastewater stream is the smallest degree of 
dilution that can avoid reasonable potential to exceed water quality criteria. Of the permits exam-
ined during the late 1990s and early 2000s by U.S. EPA Region 6 staff, 58% included critical 
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dilution limits of >50%, suggesting effluent-dominated or dependent conditions under low flows. 
Critical dilution limits of 100%, indicating effluent-dependent conditions, were observed in 37% of 
permits evaluated (Brooks et al. 2006). 
As noted earlier, in-stream hydrology is an important consideration because effluent-dominated 
conditions present worst-case locations for API exposures in developed countries. Daughton (2002) 
proposed the term "pseudopersistent" to describe the unique exposure scenarios to APIs in these 
ecosystems. Although APIs are designed to be stable enough to ensure parent stability through 
the manufacturing-distribution-prescription-treatment continuum, APIs are generally considered to 
have lower environmental persistence than conventional priority pollutants. However, human APIs 
(and ingredients from PCPs) may be unique compared with conventional contaminants because 
they can be continuously introduced via effluent to a receiving system (Daughton 2002). Under 
these conditions the half-lives of the compounds may exceed in-stream hydrologic retention times, 
increasing the effective exposure duration experienced by organisms residing in the receiving 
system (Ankley et al. 2007). Of course, increased effective exposure duration could also apply to 
other effluent contaminants in these scenarios. Unfortunately very little information is available for 
in-stream magnitude, frequency, and duration of exposure to APIs originated from any of numerous 
sources, so the influence of hydrology on "pseudopersistence" of APIs requires more study. 
8.3.2.2 Wastewater Treatment Technologies 
Though effluent-dominated or effluent-dependent conditions described earlier deserve particular 
attention for API exposures in developed countries, treatment capabilities of WWTPs discharging 
to these systems are likely to be relatively high because effluent dilution limits are generally more 
stringent to meet effluent quality goals (e.g., water quality criteria, whole effluent toxicity). An 
understanding of treatment capabilities for APTs has grown in recent years, though an understand-
ing of site-specific loading of APIs will be influenced by a number of factors. The most comprehen-
sive study to date was commissioned by American Water Works Association Research Foundation 
(Snyder et al. 2007). During this study, various treatment technologies were evaluated singularly 
and in combination for their efficiencies in removing select APIs, PCPs, and endocrine-disrupting 
compounds. 
Snyder et al. (2007) concluded that conventional processes for coagulation, flocculation, 
sedimentation, and ultraviolet radiation (for disinfection) were largely ineffective for many of the 
target analytes examined, including a number of APIs. More advanced treatment technologies such 
as reverse osmosis, activated carbon, advanced oxidation processes, and nanofiltration were con-
sidered relatively highly effective for target analytes, though API structural properties influenced 
treatability among tested technologies (Snyder et al. 2007). This study highlighted the importance 
of understanding ecological risk from specific APIs prior to making risk-based management deci-
sions (U.S. EPA 1999), because risk mitigation technologies such as advanced treatment processes 
for APIs may be cost-prohibitive for municipal dischargers. 
In developing countries, however, advanced WWTP technologies might not be employed, regu-
latory guidelines not be developed, or enforcement of regulations may not be as prevalent as in the 
developed world. A recent study by Larsson et al. (2007) examined select APIs in effluent from a 
WWTP in Patancheru, India. This WWTP was reported to primarily receive influent wastewater 
from approximately 90 pharmaceutical manufacturers. Although isotope dilution was not employed 
and extraction efficiencies were not reported in this screening study, high levels of several APIs were 
reported in grab samples collected on two consecutive days, ranging from 90 (ranitidine) to 31,000 
(ciprofloxacin) flg/L. Further, 21 of 59 target pharmaceuticals were reported earlier to be I flg/L 
(Larsson et al. 2007). Levels of most of these APTs represent the highest concentrations reported 
in the peer-reviewed literature, highlighting the importance of understanding site-specific ecolog-
ical exposure and risks in less developed countries. A follow-up study (Fick et al. 2009) revealed 
concentrations of APTs surface- and well-water levels that may be the highest yet reported in the 
ambient environment-above the ppm (mg/L) level. Lakes receiving treated wastewater effluent 
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contained ppm levels of three f1uoroquinolone antibiotics (ciprofloxacin, norfloxacin, and enoxa-
cin) and cetirizine, an antihistamine. These studies show that in special cases, aquatic exposure 
levels have the potential to reach concentrations that exceed human plasma levels achieved during 
therapeutic treatment. 
8.3.3 SITE-SPECIFIC pH AND API pKA 
Many APIs are weak acids or weak bases. Because these compounds are ionizable, their pKa and 
the pH of the medium influence the proportion of the molecules present in a non ionized form. The 
nonionized/ionized ratio of an API in a matrix (e.g., body compartment) is an important consid-
eration in pharmacology and toxicology-influencing absorption and disposition profiles of APIs 
following dosage in target organisms (Klaassen and Watkins 2003). As noted earlier, additional 
uptake mechanisms are possible for APIs, but the nonionized form of a drug is more nonpolar and 
thus considered to passively cross membranes more readily than the ionized form of an API (Kah 
and Brown 2008). Such observations for APIs are included in physiological-based pharmacokinetic 
models, which are discussed in greater detail later. 
For conventional contaminants, such as pentachlorophenol and ammonia, the more nonion-
ized form is believed to be more bioavailable and toxic to aquatic life. Subsequently, the U.S. 
EPA developed National Ambient Water Quality Criteria for ammonia (U.S. EPA 1985) and 
pentachlorophenol (U.S. EPA 1986) that incorporate adjustment factors for site-specific differ-
ences in pH. Similarly, the non ionized forms of APIs are likely more bioavailable and potentially 
more toxic to aquatic life residing in receiving systems (Kah and Brown 2008). An example is 
provided in Figure 8.2 for the SSRIs f1uoxetine (Figure 8.2a) and sertraline (Figure 8.2b), which 
were reported in three fish species in a receiving system with in-stream pH commonly >8.0 
(Brooks et al. 2005). 
For chemicals that can ionize, distribution into lipid is a function of the pH. For these dissociative 
systems, a "distribution" coefficient "D" (as opposed to partition coefficient) is calculated; D can be 
viewed as an "apparent" partition coefficient-one that depends on pH and the degree of ionization. 
Both f1uoxetine (pKa = 10.05 ± 0.10) and sertraJine (pKa = 9.47 ± 0.40) are weak bases with log D 
values and associated BCFs that are predicted to increase over environmentally relevant pH ranges 
(Figure 8.2); however, the liposome-water distribution coefficient (log D1ipw) may be more useful 
than log D for predicting accumulation of ionizable compounds (Escher et al. 2000). 
As presented previously, Nakamura et al. (2008) observed f1uoxetine toxicity for, and BCFs in, 
Japanese medaka to increase with increasing pH in laboratory studies. Valenti et al. (2009) reported 
similar toxicity-pH observations with juvenile fathead minnows exposed to sertraline. Further, 
Valenti et al. (2009) performed a time-to-death fathead minnow study with 500 Ilg/L of sertraline, 
and estimated associated LT50 values of >48,31.9, and 4.9 h at pH treatment levels of 6.5, 7.5, and 
8.5, respectively. Such observations support the findings of Nakamura et al. (2008) because if more 
non ionized sertraline exists at higher pH treatment levels, then sertraline should be more bioavail-
able and more readily absorbed by juvenile fathead minnows, resulting in the observed more rapid 
onset of mortality at increasingly higher pHs. 
Nakamura et al. (2008) further used pH and the BCF values calculated in their study to predict 
aqueous f1uoxetine levels in Pecan Creek, TX that would result in reported levels of accumulation 
of f1uoxetine in fish (Brooks et al. 2005). Interestingly Nakamura et al. (2008) imputed that the 
f1uoxetine concentrations in Pecan Creek, TX should be -11 ng/L, which is representative of flu ox-
etine levels routinely observed in Pecan Creek over the past few years (Brooks unpublished data). 
However, these estimates do not account for other routes of exposure such as diet. Brooks et al. 
(in preparation) have quantitated levels of sertraline, norsertraline, f1uoxetine, and norfluoxetine in 
periphyton and benthic macroinvertebrates from Pecan Creek, suggesting that future studies should 
understand the relative contribution of bioconcentration to bioaccumulation of these and other APls 
in aquatic life. 
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FIGURE 8.2 Bioconcentration factors and log D values for the selective serotonin reuptake inhibitors 
f1uoxetine (a) and sertraline (b) across environmentally relevant pH ranges. Values calculated using Advanced 
Chemistry Development (ACD/Labs) Software VS.l4. 
8.3.4 ADVANCEMENT IN TISSUE SAMPLING AND SURROGATE MONITORING 
Site-specific exposure may be estimated in situ using surrogate measures of API bioavailability. 
Passive sampling devices have long been used for obtaining estimates of aquatic uptake; see over-
views in Greenwood et a1. (2007). A variety of devices have been developed for field-deployment 
to emulate the uptake of xenobiotics by fish via diffusion into lipid. These include semipermeable 
membrane devices (SPMD) (Barber et a1. 2006) and the polar organic chemical integrative sampler 
(POCIS) (Vermeirssen et a1. 2005). Bayen et a1. (2009) discuss the variables in the use of passive 
sampling devices for predicting uptake of hydrophobic chemicals, which would be applicable to 
only a portion of APIs. Key characteristics for the device and organism are surface-to-volumel 
weight ratios. 
Nonlethal sampling via biopsy has been used for other pollutants but not yet for APls. One 
example is the acquisition of tissue samples from fins (Rolfhus et a1. 2008). 
Conventional sampling devices and tissue sampling approaches suffer from cost for the devices 
and expenses associated with sample preparation, including organic solvents (and disposal) and 
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analyst time. More significantly, with respect to exposure studies, tissue extraction usually only 
measures total levels of the analyte as opposed to free, unbound residues that are more readily bio-
available. A recently developed approach uses in-vivo sampling by way of implanted fibers coated 
with the sorbent poly(dimethylsiloxane) in a SPME format (Zhou et al. 2008); another approach 
for establishing chemical activity in tissues is the silicone membrane equilibrator developed by 
Mayer et al. (2009). SPME avoids many of these limitations and serves to collect only free resi-
dues. However, an understanding of the utility of various SPMDs, SPMEs, and POCIS technologies 
across API classes ranging in physiochemical properties under varied environmentally relevant pH 
ranges is not available at this time. 
8.4 MODELS FOR PREDICTING EXPOSURE AND POTENTIAL EFFECTS OF APls 
8.4.1 BACKGROUND AND PRIORITIZATION 
Although several recent book chapters reviewed approaches for predicting human API (Versteeg 
et al. 2005) and veterinary API (Metcalfe et al. 2008) concentrations in aquatic systems, limited 
approaches are available for predicting exposure within an organism and linking exposure to poten-
tial ecological effects. Prospective assessments often include trigger values for further testing based 
on predicted environmental concentrations (e.g., 1 f./g/L for human APIs in the United States). These 
predicted concentrations are often driven by production volumes and associated patient uses, and do 
not consider API potency. Ankley et al. (2007) reviewed assumptions associated with API trigger 
values based on usage, noting that a trigger value of 1 f./g/L equates to a production volume in the 
United States of 44,000 kg/year, but that this approach is not appropriate for highly potent APIs 
such as EE2. Despite its very low production volume, it is highly potent (Cmax is less than 100 pg/mL, 
where Cmax is the maximum plasma level reached during therapeutic dosing) and lipophilic (log 
P - 4). 
Because APIs represent compounds with a wide range of potencies and physiochemical proper-
ties (log P or D, pKa), screening approaches that examine similar properties for the large expanse 
of thousands of APIs may be useful for prioritizing substances for further bioaccumulation or eco-
toxicity studies. Although risk-based prioritization approaches have been developed for veterinary 
APIs (Boxall et al. 2003, Capleton et al. 2006, Koois et al. 2008) and pesticide transformation 
products (Sinclair et al. 2006), few approaches have been published for prioritizing human APIs 
(see Gunnarsson et al. 2008, Kostich and Lazorchak 2008). A powerful tool for such studies may be 
derived from probabilistic hazard/risk assessment. Chemical toxicity distributions (CTDs) represent 
robust probabilistic approaches for predicting a specific toxicological response in a model organism 
(e.g., fathead minnow reproduction) associated with the universe of chemicals that share a com-
mon MOA. CTDs are derived by plotting toxicity property data (e.g., NOAELs for fathead minnow 
reproduction) for a number of chemicals against a probability scale. This represents an approach 
conceptually similar to SSDs, which plot a distribution of toxicity benchmarks for various species 
exposed to a common chemical. Much like SSDs, which allow an assessor to estimate the concen-
tration below which a certain percentage of aquatic species would respond to a chemical (e.g., an 
HC5 or 5th centile value), a CTD allows for predictions of the concentration below which a specific 
percentage of chemicals with a common MOA (or theoretically any other common data property) 
will still elicit a specific response (e.g., below the NOAEL for fathead minnow reproduction). For 
example, CTDs were previously demonstrated to predict toxicity of carcinogens (Munro 1990), anti-
biotics (Brain et al. 2006), estrogen agonists (Dobbins et al. 2008), and the antimicrobial parabens 
(Dobbins et al. 2009). This approach is particularly useful for environmental contaminants such 
as APIs that have limited environmental exposure information (Brain et al. 2006, Dobbins et al. 
2(09). CTDs were further demonstrated to exhibit diagnostic capabilities to predict differences in 
sensitivities among common in vitro and in vivo models of estrogen agonist activity (Dobbins et al. 
200S). CTDs are conceptually similar to but provide a more quantitative approach than Threshold 
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of Toxicological Concern methodologies (Gross et al. 2010) previously used in human health risk 
assessment (Brooks et al. 2009a). 
We explored the utility of using probabilistic therapeutic distributions (PTDs), which are identical to 
CTDs with the exception being that therapeutic plasma data (Cmax) are examined, to represent the full 
spectrum of API potencies. Figure 8.3 presents a PTD of Cmax values for 275 human APIs, and Table 8.5 
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FIGURE 8.3 Probabilistic therapeutic distribution (PTD) of human plasma emax values for 275 Active 
Pharmaceutical Ingredients (APIs; r2 = 0.99). For APIs with multiple emax values, distribution values are emax 
concentrations associated with the most common dosage; also see Table 8.5. 
TABLE 8.5 
Probabilistic Therapeutic Distribution 
Centiles and Predicted Cmax Values Derived 
from Cmax Plasma Concentrations for 275 
Human Pharmaceuticals; also See Figure 8.3 
Centile Value em., (jJg/ml) 
1% 0.0001169 
5% 0.00107 
10% 0.00347 
25% 0.0248 
50% 0.221 
75% 1.97 
90% 14.15 
95% 45.97 
99% 419.32 
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identifies concentrations associated with specific centiles (e.g., 5th, 95th centile) of the distribution. Using 
this PTD approach ~ 25% of human APls are predicted to have Cmax values less than 0.0248 or greater 
than 1.97 flg/mL (Table 8.5). Chemical classes with relatively high potencies include endocrine active 
substances (n = 12; range: 0.0000922-0.0595 flg/mL), whereas NSAIDs (n = \1; range: 0.705-110 flg/ 
mL) have relatively lower potencies. 
Although the PTD approach presented here only examined Cmax values to compare relative 
potencies among a wide range of APls, PTDs could be developed for other API property data 
useful for predicting accumulation (e.g., BCF). For example, maximum log D (or log K1ipw) values 
for weak acids and weak bases could be examined over an environmentally relevant pH range 
(e.g., pH 6-9). Maximum log D PTDs could be developed for weak acids and weak bases (e.g., 
pH 9 used for a weak base with a pKa > 9) to predict the proportion of APIs that may be expected 
to have log D values greater than some screening threshold (e.g., -3) at environmentally relevant 
conditions. Such approaches could provide useful rankings of relative therapeutic property data and 
for predicting potential property data of new medicines within API classes (Brooks et al. 2009a). 
For example, Berninger and Brooks (2010) provide a more extensive examination of the utility of 
PPDs. Specifically PPDs to prioritize pharmaceutical classes for further study, based on a statis-
tically significant relationship between a mammalian margin of safety corollary and fish acute-
to-chronic ratios, when fish chronic responses were plausibly linked to therapeutic MOA (Berninger 
and Brooks 2010). 
8.4.2 PHYSIOLOGICAL-BASED PHARMACO(ToXICO)KINETlC (PBPK) MODELS 
Pharmacokinetics often utilizes one- and two-compartment models to examine potential systemic 
effects following exposure. These relatively simple approaches model the distribution of a con-
taminant (or therapeutic) in a whole body or plasma compartment (one compartment). In a two-
compartment model, disposition in a whole body or plasma compartment is coupled with a second 
compartment, which represents movement to storage depots (e.g., fat) or metabolism. Although 
these models are useful for deriving parameters such as clearance rates, multicompartment PBPK 
models are also useful tools for predicting uptake and disposition of environmental contaminants. 
These more advanced models can: incorporate physiological processes to predict distribution of a 
compound among various tissues; extrapolate among organisms, exposure routes and ages; and esti-
mate internal dose (Andersen and Dennison 2002, Barton et al. 2007). Subsequently, PBPK models 
are routinely used in human health risk assessments (US. EPA 2006) and increasingly developed 
for ecotoxicological applications in fish models (see other chapters in this book). 
Whereas a number of investigators have examined the utility of physiological models for predict-
ing environmental contaminant uptake and distribution in fish (Erickson et al. 2006a, 2006b, 2008), 
Erickson et al. (2006a), recently developed a model in trout for describing uptake and elimination of 
ionizable organic chemicals (chlorophenols) at fish gills. Erickson et al. (2006b) further applied this 
model to several weak acids with pKa values ranging from 4.74 to 8.62 and log Kow values ranging 
from 2.75 to 5.12. This model was found to predict uptake of ionizable chemicals based on phys-
iochemical properties under the exposure conditions evaluated with trout (Erickson et al. 2006b). 
Similar approaches with APIs would be useful for predicting uptake. Although multicompartment 
PBPK models have not been developed for ionizable APIs and fish, such efforts could be critical to 
estimate internal dose of APIs to target tissues under environmentally realistic API exposures and 
pH gradients. This area deserves additional study to characterize API exposure in various tissues of 
aquatic organisms where therapeutic targets are present. 
8.4.3 THE HUGGETT MODEL 
In addition to exhibiting wide ranges in potency, lipophilicity of APIs demonstrates marked 
variability along a polar-nonpolar continuum. Accounting for such differences in lipophilicity and 
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potency, Huggett et al. (2003) proposed the following model to prioritize human APIs for additional 
chronic testing (Equation 8.l): 
FssPC = EC X (PBloodWater) (8.l) 
where FssPC is predicted fish steady-state plasma concentration, EC is the aqueous exposure 
concentration, and P Blood:Watcr is the predicted partition coefficient in blood from aqueous expo-
sure medium. Fish were selected for model development because more information is available for 
these organisms, and fish appear to contain relatively high evolutionary conservation of API tar-
gets (Huggett et a1. 2003, Gunnarsson et al. 2008). The Huggett Model (Huggett "mammalian-fish 
leverage model") simply proposes that the higher an API's predicted plasma concentration in fish 
(FSSPC) compared with that of a mammal (e.g., human therapeutic plasma concentration [HTPC] 
or a Cmax value) the higher the likelihood of chronic adverse effects (Huggett et al. 2003). As the 
effect ratio (ER) (Equation 8.2) inflates, the likelihood of an API causing chronic effects drops. As 
the ER drops, and especially when it becomes less than 1, adverse effects become more probable. 
(8.2) 
The core calculation of this model (PBloodWatcr) employed an empirical relationship between 
log Kow and plasma concentrations in trout and in vitro partitioning data, which was developed for 
hydrophobic compounds by Fitzsimmons et al. (2001; Equation 8.3): 
log PBlood:Water = 0.73 x log Kow ~ 0.88 (8.3) 
Though Huggett et a1. (2003) used Equation 8.3 for development of Equation 8.2, another rela-
tionship (Equation 8.4) reported by Fitzsimmons et al. (2001) appears even more important for APls 
with apparent log P values lower than 2: 
log PBW = log [(100 711ogKow x 0.16) + 0.84J (8.4) 
To derive Equations 8.3 and 8.4, Fitzsimmons et a1. (2001) coupled in vivo log PBloodWater values 
for compounds having log K.,w values ranging from 3.1 to 8.2 with previously published in vitro data 
for compounds with lower log Kow's (Bertelsen et al. 1998). 
Brooks et a!. (2009a) extended this approach for fish exposed to veterinary medicines 
(Equation 8.5): 
(8.5) 
where EICPlasma is the concentration in fish plasma resulting from environmental exposure. Similar 
to the Huggett Model, the EICPlasma value proposed by Brooks et a!. (2008) would include an uptake 
prediction from aqueous exposure, and Cmux would be derived from animal efficacy studies (e.g., 
in livestock). As previously noted, the study by Fick et al. (2010) identified accumulation of select 
pharmaceuticals approaching or exceeding human therapeutic levels in plasma of caged fish below 
effluent discharges. 
It is important to note, however, that the models of Huggett et al. (2003) and Brooks et al. (2009b) 
considered neither bioaccumulation through dietary sources nor the metabolism potential once an API 
is absorbed into the fish. They also did not include log D in model derivation. Despite its limitations, the 
Huggett Model appears to provide a reasonable screening approach that is amenable to further refine-
ment. Remaining to be determined is whether: (i) a relationship similar to the equation of Fitzsimmons 
et al. (2001) (Equation 8.3) would be appropriate for ionizable APIs if, for example, log Kow were 
substituted with log D; (ii) dietary exposure is a concern for specific APIs; (iii) clearance rates could be 
predicted in fish using mammalian or target organism information and allometric scaling approaches 
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(if the metabolic pathway for eliminating an APT [e.g., CYP450 isoenzyme] is present in a study spe-
cies); or (iv) API target densities and functional responses would be different between mammals and 
fish. Similar approaches have not been developed for other organisms (e.g., invertebrates). 
Summary 
The preponderance of studies published on APIs as contaminants in the aquatic environment 
have focused on establishing the presence of APIs in the abiotic environment-primarily levels 
in water and sediment. Comparatively few studies document tissue concentrations. Even fewer 
studies examine bioaccumulation from sediments. This is a major limitation in being able to 
establish correlations between biological effects observed in the field with exposure, especially 
because exposure usually involves multiple chemical (and other) stressors acting in unison or 
in sequence. This is a critical step in being able to establish cause and effect. Few data are 
available on tissue levels from free-ranging, migratory fish in locales not directly impacted by 
sewage effluent. Even fewer controlled exposure studies follow the emergence of any type of 
biological effect. As one example, a range of effects have been reported for trout chronically 
exposed to a minimum of 500 ng/L of diclofenac for 21 days (Mehinto et al. 2010). 
As part of the EPA's National Rivers and Streams Assessment (NRSA) study (U.S. EPA 
2008b), plans include analysis of water and fish fillets from 183 urban rivers in the United States 
for 54 APIs targeted from a range of therapeutic classes, as well as for four synthetic musks and 
two of their metabolites (Blocksom et al. 2009). The NRSA will attempt to provide the largest 
dataset yet on the occurrence of multiple APIs in fish tissue. Sample collection began in 2008, 
and plans are to report on the data by 201l. 
A concerted effort is needed to synthesize the data and knowledge that have already been 
published, especially in the non-English literature not covered in this review (Daughton 2009). 
This knowledge basically languishes in the published literature, reducing the ability to ration-
ally prioritize and design the most needed research. As such, it is also unable to prevent dupli-
cation of effort. While actual empirical data on BCFs or tissue levels of APTs are extremely 
scarce, a range of modeling techniques can be used to prioritize APIs according to predicted 
BCF or known tendency for active transport. A limited list of APIs could then be targeted for 
in-field monitoring to corroborate predictions. Computed BCFs from models are more avail-
able than empirical BCFs, but these have never been compiled in any database. Further, BAFs 
(and BSAFs) for APIs should be further considered to account for site-specific pH influences 
on ionization and partitioning, dietary exposures, and potential trophic transfer. The literature 
focusing on veterinary drug use in aquaculture, although limited primarily to antibiotics and 
steroids, may be of use in extrapolating to the ambient environment. 
Predictive models and studies under controlled laboratory conditions directed at APIs that 
have yet to be identified in aquatic tissue from the wild could be more widely used to better 
inform the prioritization of APTs for field biomonitoring. For example, the fact that some syn-
thetic progestins (i.e., levonorgestrel and 19-norethindrone) have a high affinity for fish sex hor-
mone-binding globulin, points to the possibility that their enhanced uptake could lead to their 
being found in tissues. Observations by Fick et al. (2010) for levonorgestrel appear to confirm this 
perspective. This is critical because synthetic progestins have been identified to adversely affect 
fish reproduction at low or even sub-part-per-trillion concentrations (Zeilinger et al. 2009). 
More study is needed on the bioaccumulation of metabolites, especially those that are bio-
active themselves. Likewise, more needs to be known about halogenated DBPs, which might 
very well have higher BCFs than their parent APIs. Such data are important with regard to 
trophic chain transfer and accumulation and with respect to human consumption, particularly 
in effluent-dominated or dependent ecosystems. Given the probably significant role in medicine 
to be played by nanomaterials (especially in better targeting drug delivery), studies are needed 
on the uptake of engineered nanoparticles; see overview by Baun et al. (2008). 
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Exposure studies under controlled laboratory conditions need to use concentrations that 
have relevance to the environment. Earlier studies (as late as the 1990s) focused on acute tox-
icity studies, yielding results using concentrations that far exceeded realistic ambient levels. 
Concentrations that occur in the aquatic environment are often orders of magnitude lower than 
those used in many controlled studies. Such low concentrations are capable of eliciting sublethal 
effects that are much more difficult to detect, especially those leading to subtle behavioral 
effects or changes that are of delayed onset. Further studies relating tissue-specific internal 
exposures to sublethal responses predicted by API MOAs are warranted. 
Perhaps the gold standard for the study of exposure is the "lossless" model using radiolabeled 
APIs. This permits attempts at achieving mass balance closures for residues distribution over 
the whole body (e.g., Junker et al. 2006) and in target tissues where therapeutic targets for many 
APIs are present at highest densities. Even with radiolabeled materials, however, it is rare that 
mass balances can be fully achieved (Roffey et al. 2007). Unfortunately, radiolabeled APIs are 
expensive and not widely available, presumably precluding such studies to date. 
A major question is whether measurements of whole body or of certain tissues or compart-
ments accurately reflect the internal dose at target organs better than exposure measurements 
imputed from aqueous concentrations. While assumed to better represent exposure than do 
concentrations external to the organism, the actual bioavailability of these residues is essentially 
unknown. Given the exposure continuum that ultimately leads to stressor-receptor interaction, 
stressor residues residing in tissues such as fat depots, cartilage, bone/scale, gonads, and blood 
may not yet have reached their ultimate destinations where maximal biological activity can be 
affected. New approaches using biopsy or in vivo equilibrative extraction of target tissues could 
illuminate this unknown. As an example, SPME has been used to examine in vivo the body/tis-
sue concentrations of free stressors (Wen et al. 2006, Zhou et al. 2008). Other new approaches 
for measuring tissue concentrations include caudal fin biopsy (e.g., Rolfhus et al. 2008). 
The difficulty in assessing tissue concentrations is the driving force behind the development 
of physical model systems that can emulate biological exposure. A number of approaches have 
evolved, primarily aqueous sampling devices that act as surrogates for whole-body exposure (to 
estimate concentrations within the body). These devices include SPMD, SPME, and POCIS. 
However, the utility of such technologies to be predictive of accumulation in organ systems within 
an organism where API targets are present is not understood. Coupling radiolabeled API studies 
with development of PBPK fish models presents a useful approach for future efforts, particularly 
for understanding uptake of ionizable APIs across environmentally relevant pH gradients. 
Perhaps the ultimate question is whether the assessment of exposure is truly meaningful if the 
"totality" of exposure is not considered-that is, all the stressors to which an organism is exposed, 
both anthropogenic and naturally occurring. This includes the universe of chemical stressors and 
the numerous other stressors, including those that are physical, electromagnetic, radiological, or 
biological. Relative risks of APls for aquatic organisms in the field, compared with other stres-
sors, remains a significant research need. Perhaps the major question with regard to APIs in the 
aquatic environment is the importance of long-term, low-level, multistressor exposure. 
A range of other gaps and limitations with respect to better understanding APIs in aquatic 
organisms is summarized in Table 8.6. 
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TABLE 8.6 
Tissue Levels of APls in Fish: limitations, Gaps, and Unique Aspects 
limitation of Data 
Limited data on tissue 
concentrations 
Ecotoxicity studies 
rarely report tissue 
occurrence of APIs 
Linkage between 
tissue residues and 
biological effects 
Tissue data almost 
always report total 
concentrations 
Limited scope of 
targeted anal ytes 
Exposure 
concentration 
verification in 
laboratory studies 
Exposure duration and 
frequency 
Self-biasing 
Tissue and 
measurement basis 
Example/Explanation 
Of the thousands of publications covering the many 
aspects of APIs as environmental contaminants, only 
about 50 published studies have reported API 
concentrations in fish tissues. 
Ecotoxicity studies of APIs have been conducted to 
assess effects endpoints. They generally provide 
little data or insights regarding either the parameters 
involved with internal exposure or tissue 
concentrations. 
Do concentrations in aquatic tissues better represent 
the potential for toxicity than concentrations free in 
the surrounding aquatic environment? Do they better 
reflect the actual dose? Tissue residues in target 
systems could reflect relevant internal dose 
compared to whole organism CBR approaches. 
The portion of the total tissue-level of an API that is 
bioavailable is almost always unknown; unknown 
portions can be sequestered as adducts. Free versus 
bound residues are rarely distinguished, likely 
because radiolabeled APIs are scarce. 
Extremely few APIs have been targeted for tissue 
analysis. Empirical tissue levels in nonaquacultured 
fish have been published for roughly only 30 
different APIs, excluding antibiotics (roughly only 
20 in samples from native environments); the vast 
majority of all possible APls identified in the aquatic 
environment (and those not yet identified) have 
never been targeted for tissue analysis. 
With aqueous exposure under controlled conditions, 
the actual dosage needs to be measured; the nominal 
added dosage is likely to be different than the 
measured dosage (as a result of sorption to container 
walls and other solids, degradation, etc). 
Little is known regarding the life-cycle body 
burden of APIs. Multigenerational studies are 
extremely rare. 
APIs with the lowest MDLs have the best chance of 
being detected. Those with the highest MDLs have 
the lowest chance of being detected. API MDLs for 
a particular tissue can vary by more than 2 orders of 
magnitude. This means that APls commonly present 
in tissues but having high MDLs might not be 
detected. 
API residues have been reported in a wide range of 
tissues. They are also nonnaliICed on ditlerent bases 
(e.g" wet weight, dry weight, lipid content. etc.). 
Additional Details 
Only a subset of these studies has 
reported residues in fish exposed in 
wild, native environments. 
Very few studies have examined 
internal dose (in plasma) following 
exposure in the field. 
Total residue levels often involve 
conjugates, which do not pose a 
readily bioavailable source. 
The limited published data for tissue 
residues are focused primarily on 
antibioticslbiocides and natural and 
synthetic sex steroids; very few 
studies have targeted the 
simultaneous presence of multiple 
APls. 
Inaccurate exposure concentrations 
can lead to calculated BCFs that are 
too high or too low by one or more 
orders of magnitude. 
Multiyear monitoring studies are even 
rarer (e.g., Boehmer et al. 2004). 
Tissue concentrations below 
0.1-1 f./g/kg are rarely reported 
because this usually is below the 
method limit of detection-because 
of matrix interferences. So an 
unknown number ofAPls could be 
present at these levels. 
This makes intercomparisons between 
studies very difficult. 
continued 
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TABLE B.6 (continued) 
Tissue Levels of APls in Fish: Limitations, Gaps, and Unique Aspects 
Limitation of Data 
Mass balance 
Endogenous 
contributions 
Veterinary medicine 
exposure studies 
Controlled exposure 
studies versus 
real-world settings 
Real-world exposure 
scenarios and 
exposure 
concentrations 
Inadequate uptake 
models 
1\,. data unreliable 
Models for predicting 
BAFs 
Metabolites 
Example/Explanation 
Few studies attempt to achieve mass closure around 
the total body burden of APls and their distribution 
across all tissues. 
For the endogenous sex steroids, levels metabolically 
synthesized are augmented by unknown levels 
contributed by uptake of exogenous residues in 
water and sorbed to food. 
The vast preponderance of bioconcentration studies 
for fish has been conducted because of the concern 
for food residues resulting from API usage in 
aquaculture. Knowledge gained from these studies 
could possibly be evaluated for relevance to 
exposure in the ambient environment. 
Tissue data are primarily obtained under controlled 
exposure studies. Of the very limited studies on 
tissue concentrations, only about two-thirds have 
been obtained under ambient conditions with fish in 
their native environments. 
Tissue data obtained under controlled conditions are 
often derived from exposure concentrations far 
higher than those that occur in native environments. 
Controlled exposure studies often use exposure 
concentrations that are one or more orders of 
magnitude higher than those that exist in the ambient 
environment, to maximize the chances of detecting 
and quantifying any amounts that have been 
accumulated. 
Lipid-solubility (e.g .. as modeled by octanol-water 
coefficient) is an inadequate predictor of API uptake. 
!\" coupled with pK, (log D. log K"pw) provides a 
more realistic model. 
Published 1\,,, data are extremely variable, probably a 
result of ionization and localized charges and 
because of interaction with other ions. 
Bioaccumulation of APls cannot currently be 
modeled. 
The metabolism of APls creates the potential for 
bioconcentration of metabolites. some of which are 
bioactive themselves. 
Additional Details 
Rigorous closure studies usually 
require the use of radiolabeled APIs, 
but the commercial availability of 
radio labeled compounds is extremely 
limited. 
Exogenous contributions, even for 
endogenous steroids. can have 
origins from pharmaceuticals. 
Aquaculture studies comprise two 
major scenarios: (I) direct 
incorporation of API in fish being 
treated with high levels during 
aquaculture, and (2) indirect 
incorporation of API in wild fish that 
become exposed to aquaculture 
residues leftover from uneaten feed 
and excreted residues. 
Even in native environments, exposure 
studies are often controlled by using 
caged wild fish. More studies are 
needed using fish captured from 
waters less dominated by sewage 
effluents. 
BCFs usually drop off as exposure 
concentrations increase, leading to 
gross underestimates for real-world 
settings at much lower 
concentrations. 
Other mechanisms may be involved, 
especially those involving active 
transport, facilitating the uptake of 
polar (ionizable) APls. 
Models employed for predictions of 
physicochemical properties 
inherently vary. 
Too many variables compared with the 
conventional nonpolar pollutants 
(e.g .. legacy POPs). whose 
accumulation is dictated primarily by 
lipid-solubility and metabolism is 
minimal. 
Little is known regarding 
pharmacokinetics of APls in fish or 
other aquatic organisllls. 
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TABLE 8.6 (continued) 
Tissue Levels of APls in Fish: Limitations, Caps, and Unique Aspects 
limitation of Data 
Tissue depots/ 
reservoirs 
Tissue levels are not 
necessary for ad verse 
effects 
Significant BCFs are 
not necessary for 
adverse effects 
lnterspecies 
extrapolations 
Surrogates for 
bioconcentration 
REFERENCES 
Example/Explanation 
It is poorly understood how APIs are stored and 
accumulate in aquatic organisms. 
Important to note that internal exposure is not 
necessary for an effect when tbe target organ is 
external. 
APIs are designed to minimize accumulation during 
therapy in the body. Any build-up in aquatic tissue 
could be important, regardless of how low the BCF 
might be. 
Variance in uptake and pharmacokinetics of fish 
species makes usefulness of extrapolations 
questionable, requiring further investigation. 
Sampling devices based on partitioning of analytes 
from aqueous media (e.g., semipermeable 
membranes) have not been calibrated for fidelity to 
bioconcentration under varying field conditions and 
do not account for bioaccumulation through dietary 
routes of exposure. 
Additional Details 
Mechanisms could include adducts 
with DNA, pigments such as 
melanin, and a wide array of 
endogenous proteins (especially 
those in plasma). 
This is the case. for example, with 
exposure of the lateral-line sensory 
organ. 
Comparative metabolism and other 
potential applications of 
pharmacological "read-across" are 
largely unknown. 
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